<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1425262-B1" country="EP" doc-number="1425262" kind="B1" date="20140108" family-id="23201127" file-reference-id="242851" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146589214" ucid="EP-1425262-B1"><document-id><country>EP</country><doc-number>1425262</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-02756732-A" is-representative="NO"><document-id mxw-id="PAPP154851406" load-source="docdb" format="epo"><country>EP</country><doc-number>02756732</doc-number><kind>A</kind><date>20020725</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140553390" ucid="US-0223924-W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>0223924</doc-number><kind>W</kind><date>20020725</date></document-id></priority-claim><priority-claim mxw-id="PPC140557901" ucid="US-31013301-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>31013301</doc-number><kind>P</kind><date>20010803</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130703</date></intention-to-grant-date><search-report-dispatch-date><date>20060125</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989327957" load-source="ipcr">A61K  31/16        20060101ALI20030227BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327958" load-source="ipcr">A61K  31/21        20060101ALI20030227BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327959" load-source="ipcr">A61K  31/44        20060101ALI20030227BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327960" load-source="ipcr">C07C 233/05        20060101AFI20030227BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327961" load-source="ipcr">C07C 233/65        20060101ALI20030227BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327962" load-source="ipcr">C07D 213/06        20060101ALI20030227BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989620862" load-source="ipcr">C07C 333/08        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989621609" load-source="ipcr">C07C 333/24        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989625014" load-source="ipcr">C07C 323/62        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989627512" load-source="ipcr">C07C 329/10        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989635985" load-source="ipcr">C07D 213/20        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989637103" load-source="ipcr">C07C 329/20        20060101A I20051008RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989620649" load-source="docdb" scheme="CPC">C07C 333/24        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989620869" load-source="docdb" scheme="CPC">C07C 333/08        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989621566" load-source="docdb" scheme="CPC">C07C 323/62        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989628162" load-source="docdb" scheme="CPC">C07D 213/20        20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989629406" load-source="docdb" scheme="CPC">C07C 329/20        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989639813" load-source="docdb" scheme="CPC">C07D 213/06        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989647134" load-source="docdb" scheme="CPC">C07C 329/10        20130101 LI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132372275" lang="DE" load-source="patent-office">Acylthiole und deren Zusammensetzungen als Anti-HIV-Mittel und antiretrovirale Mittel</invention-title><invention-title mxw-id="PT132372276" lang="EN" load-source="patent-office">Acylthiols and compositions thereof as anti-HIV and anti-retroviral agents</invention-title><invention-title mxw-id="PT132372277" lang="FR" load-source="patent-office">Acylthiols et leurs compositions utilis√©s en tant qu'agents anti-HIV et en tant qu'agents anti-retroviraux</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919520281" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>GOV OF USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES NAT INST OF HEALTH</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919518374" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>THE GOV. OF USA, AS REPRESENTED BY THE SECRETARY,DEPT. OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919518320" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>INMAN JOHN K</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919529240" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>INMAN, JOHN, K.</last-name></addressbook></inventor><inventor mxw-id="PPAR919026886" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>INMAN, JOHN, K.</last-name><address><street>9200 Wadsworth Drive</street><city>Bethesda, MD 20817-2412</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919521136" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>GOEL ATUL</last-name><address><country>IN</country></address></addressbook></inventor><inventor mxw-id="PPAR919514106" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>GOEL, ATUL</last-name></addressbook></inventor><inventor mxw-id="PPAR919026888" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>GOEL, ATUL</last-name><address><street>CM-20, Sector B, Aliganj (Near Aliganj Thana)</street><city>226020 Lucknow</city><country>IN</country></address></addressbook></inventor><inventor mxw-id="PPAR919525113" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>APPELLA ETTORE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919540638" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>APPELLA, ETTORE</last-name></addressbook></inventor><inventor mxw-id="PPAR919026885" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>APPELLA, ETTORE</last-name><address><street>4112 Aspen Street</street><city>Chevy Chase, MD 20815</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919529162" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>TURPIN JIM A</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919534291" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>TURPIN, JIM, A.</last-name></addressbook></inventor><inventor mxw-id="PPAR919026887" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>TURPIN, JIM, A.</last-name><address><street>2892 Basford Road</street><city>Frederick, MD 21703</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919532551" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>SCHITO MARCO</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919533719" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>SCHITO, MARCO</last-name></addressbook></inventor><inventor mxw-id="PPAR919026889" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>SCHITO, MARCO</last-name><address><street>6225 Mazwood Drive</street><city>Rockville, MD 20852</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919026891" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>The Gov. of USA, as represented by the Secretary, Dept. of Health and Human services, National Institutes of Health</last-name><iid>101422009</iid><address><street>Office of Technology Transfer, 6011 Executive Boulevard, Suite 325</street><city>Rockville, MD 20852-3804</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919026890" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>OK pat AG</last-name><iid>100060842</iid><address><street>Chamerstrasse 50</street><city>6300 ZUG</city><country>CH</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-0223924-W"><document-id><country>US</country><doc-number>0223924</doc-number><kind>W</kind><date>20020725</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2003014062-A1"><document-id><country>WO</country><doc-number>2003014062</doc-number><kind>A1</kind><date>20030220</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549807397" load-source="docdb">AT</country><country mxw-id="DS549794225" load-source="docdb">BE</country><country mxw-id="DS549885086" load-source="docdb">BG</country><country mxw-id="DS549900017" load-source="docdb">CH</country><country mxw-id="DS549791691" load-source="docdb">CY</country><country mxw-id="DS549791692" load-source="docdb">CZ</country><country mxw-id="DS549876074" load-source="docdb">DE</country><country mxw-id="DS549794226" load-source="docdb">DK</country><country mxw-id="DS549794227" load-source="docdb">EE</country><country mxw-id="DS549891210" load-source="docdb">ES</country><country mxw-id="DS549885087" load-source="docdb">FI</country><country mxw-id="DS549885088" load-source="docdb">FR</country><country mxw-id="DS549876075" load-source="docdb">GB</country><country mxw-id="DS549794228" load-source="docdb">GR</country><country mxw-id="DS549900018" load-source="docdb">IE</country><country mxw-id="DS549885089" load-source="docdb">IT</country><country mxw-id="DS549794233" load-source="docdb">LI</country><country mxw-id="DS549807398" load-source="docdb">LU</country><country mxw-id="DS549876076" load-source="docdb">MC</country><country mxw-id="DS549891211" load-source="docdb">NL</country><country mxw-id="DS549807399" load-source="docdb">PT</country><country mxw-id="DS549891212" load-source="docdb">SE</country><country mxw-id="DS549926628" load-source="docdb">SK</country><country mxw-id="DS549885094" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63961624" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">BACKGROUND OF THE INVENTION</heading><p id="p0001" num="0001">Viruses, especially the hyper-mutable retroviruses such as HIV, can rapidly become resistant to drugs used to treat the infection. This extreme mutability has allowed HIV to diverge into two major species, HIV-1 and HIV-2, each of which has many types, subtypes and drug-resistant variations.</p><p id="p0002" num="0002">Strategies for coping with the emergence of viral drug-resistant strains include combination drug therapies (see, <i>e.g.,</i> <nplcit id="ncit0001" npl-type="s"><text>Lange (1996) AIDS 10 Supplement 1: S27-S30</text></nplcit>). Drugs against different viral proteins and drugs against multiple sites on the same protein are commonly used as a strategy to overcome the adaptability of the virus. Combination therapies for retroviruses, using, e. g. protease inhibitors and nucleoside analogues, such as AZT, ddI, ddC and d4T, can become ineffectual. The virus can develop a complete resistance to the drugs in a relatively short period of time (see, <i>e.g.,</i><nplcit id="ncit0002" npl-type="s"><text> Birch (1998) AIDS 12: 680-681</text></nplcit>; <nplcit id="ncit0003" npl-type="s"><text>Roberts (1998) AIDS 12: 453-460</text></nplcit>; <nplcit id="ncit0004" npl-type="s"><text>Yang (1997) Leukemia 11 Supplement 3: 8992</text></nplcit>;<nplcit id="ncit0005" npl-type="s"><text> Demeter (1997) J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14 (2): 136-144</text></nplcit>; <nplcit id="ncit0006" npl-type="s"><text>Kuritzkes (1996) AIDS 10 Supplement 5: S27-S31</text></nplcit>). Furthermore, although recent advances in testing HIV-SIV vaccine strategies in monkeys have been reported (see, e. g., <nplcit id="ncit0007" npl-type="s"><text>Amara et al, (2001) Science 291: 1879-1881</text></nplcit>), no antiretroviral vaccine with proven effectiveness is currently available for use in humans (see, e. g., <nplcit id="ncit0008" npl-type="s"><text>Haynes (2001) Immunol. Res. 22: 263-269</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>Bolognesi (1998) Nature 391: 638-639</text></nplcit>;<nplcit id="ncit0010" npl-type="s"><text> Bangham (1997) Lancet 350: 1617-1621</text></nplcit>).</p><p id="p0003" num="0003">The HIV-1-caused AIDS epidemic began about 20 years ago. As of December 2000, the total number of cases of HIV infection and AIDS since the start of the epidemic was<!-- EPO <DP n="2"> --> estimated to be around 58 million worldwide, which includes 22 million deaths and 36 million people living with HIV/AIDS (UNAIDS-WHO Internet report). Thus, there exists a great need for compounds that are more effective against retroviruses such as HIV-1, especially against varieties of HIV that have developed resistance to current treatments.</p><p id="p0004" num="0004">A "zinc finger" motif is a highly conserved and essential structure found in many viruses, including retroviruses such as HIV. For example, Gag and Gag-Pol proteins in the <i>Retroviridae,</i> except for <i>Spumazviruses,</i> contain a highly conserved zinc finger motif (Cysteine-Cysteine-Histidine-Cysteine: CCHC) within the nucleocapsid p7 (NCp7) protein position of the polyprotein (see definitions below). Mutations of the chelating residues in the zinc fingers yield a non-infectious virus. The absolute conservation of the metal chelating cysteine and histidine residues along with other residues of the protein, and the participation of NCp7 in essential functions during early and late phases of virus replication, identifies this feature as a particularly appealing antiviral target for hyper-mutable retroviruses, including HIV. Because these zinc fingers are identical in most retroviruses, drugs targeting zinc fingers could provide broad spectrum antivirals that would greatly reduce resistance issues.</p><p id="p0005" num="0005">Various C-nitroso compounds, disulfide-containing compounds and azoic compounds, such as cystamine, thiamine disulfide, disulfiram and azodicarbonamide (ADA) can oxidize zinc finger cysteine thiolates and induce intra- and inter-molecular disulfide cross-linking (see, <i>e.g.,</i><nplcit id="ncit0011" npl-type="s"><text> McDonnell (1997) J. Med. Chem. 40:1969-1976</text></nplcit>; <nplcit id="ncit0012" npl-type="s"><text>Rice (1997) Nature Medicine 3:341-345</text></nplcit>; <nplcit id="ncit0013" npl-type="s"><text>Rice (1997) Antimicrob. Agents and Chemotherapy 41: 419-426</text></nplcit>; <nplcit id="ncit0014" npl-type="s"><text>Rice (1996) J Med. Chem. 39:3606-3616</text></nplcit>; <nplcit id="ncit0015" npl-type="s"><text>Rice (1996) Science 270:1194-1197</text></nplcit>; <nplcit id="ncit0016" npl-type="s"><text>Rice (1993) Proc. Natl. Acad. Sci. USA 90:9721-9724</text></nplcit>; <nplcit id="ncit0017" npl-type="s"><text>Rice (1993) Nature 361:473-475</text></nplcit>; <patcit id="pcit0001" dnum="WO9609406A"><text>Henderson, et al. WO 96/09406</text></patcit>; <nplcit id="ncit0018" npl-type="s"><text>Vandevelde (1996) AIDS Res. Hum. Retroviruses 12:567-568</text></nplcit>). Cysteine thiols in each of the two zinc fingers of HIV are rapidly attacked by reagents such as Cu<sup>2+</sup>, Fe<sup>3+</sup>, C-nitroso compounds, disulfides maleimides, <i>alpha</i>-halogenated ketones and nitric oxide derivatives, with simultaneous loss of the native protein structure. For example, treatment of intact HIV-1 with an oxidizing agent, such as 3-nitrosobenzamide, a C-nitroso compound, induces disulfide linkage of the nucleocapsid protein and inactivates viral infectivity through oxidation of the zinc fingers (<nplcit id="ncit0019" npl-type="s"><text>Rice (1993) Nature 361:473</text></nplcit>; <nplcit id="ncit0020" npl-type="s"><text>Rice (1993) Proc. Natl. Acad. Sci. USA 90:9721-9724</text></nplcit>). C-nitroso compounds can also inactivate eukaryotic CCHC zinc finger containing poly(ADP-ribose) polymerase (<nplcit id="ncit0021" npl-type="s"><text>Buki (1991) FEBS Letters 290:181</text></nplcit>). However, these compounds tend to be toxic, have poor solubility and bioavailability, and are quickly reduced and inactivated in biological solutions.<!-- EPO <DP n="3"> --></p><p id="p0006" num="0006">It has recently been shown that certain compounds containing acylthio groups interact with the NCp7 zinc fingers via their acylthiol moiety. This interaction involves an acyl transfer from the acylthiol to a target cysteine sulfur atom and does not require an oxidation step as with the above-mentioned compounds (<nplcit id="ncit0022" npl-type="s"><text>Turpin et al. (1999) J. Med. Chem. 42:67-86</text></nplcit>; <nplcit id="ncit0023" npl-type="s"><text>Basrur et al. (2000) J. Biol. Chem. 275:14890-14897</text></nplcit>). Various members of this class of acylthiol compounds frequently exhibited acceptable antiviral potency. Pyridinioalkanoyl thioesters (PATEs) exhibited superior anti-HIV-1 activity with minimal cellular toxicity and showed appreciable water solubility. PATEs were shown to preferentially target the NCp7 C-terminal zinc finger when tested against other molecular targets. These compounds thus possessed broad spectrum antiviral activity, particularly against retroviruses such as HIV.</p><p id="p0007" num="0007">Despite the promising activity of the PATE compounds, the compounds of the present invention provide a significant advance in the treatment of viral infections. The PATE compounds are charged species, and as such they are quite hygroscopic. This makes isolation and purification difficult. More importantly, it increases hydrophilicity so much that uptake is inhibited and excretion is accelerated. As a result, those compounds have poor delivery characteristics for oral administration. Furthermore, many compounds of the present invention show improved hydrolytic stability in test systems containing serum, which are used to estimate the <i>in vivo</i> lifetime of compounds to be evaluated as drug candidates.</p><p id="p0008" num="0008">The compounds of the present invention possess broad spectrum antiviral activity like the PATEs. However, the acylthiols and thiols of the present invention are generally neutral species at physiological pH, so they provide better delivery characteristics than the PATE compounds. The acylthiol compounds of the present invention have increased <i>in vivo</i> stability, which allows more efficient delivery of the active acylthiol species to the targeted zinc finger viral proteins. Compounds of the present invention also possess other advantages, such as greater <i>in vivo</i> stability and greater ease of synthesis, isolation, purification, and storage, which make them still more advantageous relative to the PATEs. The compounds of the present invention are thus useful for the prevention and treatment of retroviral infections, for the preparation of inactivated viruses, and for the detection and production of antibodies to inactivated viral proteins.</p><p id="p0009" num="0009">The compounds of the present invention, by virtue of their antiviral activity, are also useful for the manufacture of compositions that can be used to inactivate viruses <i>in vitro</i> or <i>in vivo.</i> These compositions can be used to inactivate viruses to prevent the transmission of a viral infection, to treat a viral infection, or to prepare an inactivated virus as, for example, to prepare a vaccine. They are especially useful for the manufacture of medicaments that can be<!-- EPO <DP n="4"> --> used to treat mammals infected with viral diseases, particularly retroviral diseases such as, for example, HIV.</p><p id="p0010" num="0010">From<nplcit id="ncit0024" npl-type="s"><text> Goel et al. (Bioorganic &amp; Medicinal Chemistry Letters 12 (2002) 767-770</text></nplcit>), there are known benzamide-based thiolcarbamates that exhibit antiviral activity and from <nplcit id="ncit0025" npl-type="s"><text>Song et al. (Bioorganic &amp; Medicinal Chemistry 10 (2002) 1263-1273</text></nplcit>), there are known amino acide amide ligand-based pyridinioalkanoyl thioesters with anti-HIV activity. In contrast, the present invention provides different chemical compounds that in addition are neutral species at physiological pH.</p><heading id="h0002"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0011" num="0011">The invention provides compounds, compositions containing such compounds, and methods for using such compounds and compositions for the treatment of viral infections, particularly those caused by retroviruses. These compounds and compositions are also useful to inhibit the transmission of such viruses, to inactivate such viruses on surfaces or in biological tissues or samples, and to detect the presence of zinc finger proteins derived from such viruses.</p><p id="p0012" num="0012">As such, the present invention provides the following compounds:
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="160" he="55" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="161" he="51" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="5"> --></p><p id="p0013" num="0013">The invention also includes pharmaceutically acceptable salts of the compounds described.</p><p id="p0014" num="0014">In another embodiment, the present invention relates to a pharmaceutical composition including at least one compound of the present invention or a pharmaceutically acceptable salt thereof. Such compositions may optionally include a second anti-retroviral compound such as, for example, a protease inhibitor, a reverse transcriptase inhibitor, an integrase inhibitor, a fusion inhibitor and an attachment inhibitor.</p><p id="p0015" num="0015">The compounds of the present invention can be used for treating or preventing viral infections. Pharmaceutical compositions comprising at least one compound of the present invention can be administered by any known method to prevent or treat an infection caused by a virus or retrovirus that is sensitive to the compounds of the present invention. For example, the compound can be administered topically, as to a mucosal surface, e. g., intra-vaginally or intra-rectally, or, as an inhalant, to inhibit the transmission of a virus. Alternatively, the compositions can be administered parenterally (including intravenously), intrathecally, subcutaneously, orally and the like.</p><p id="p0016" num="0016">In alternative aspects, compositions comprising at least one compound of the present invention are administered to a human as a pharmaceutical formulation, or to an animal as a veterinary pharmaceutical formulation.</p><p id="p0017" num="0017">In one aspect, these compositions further comprise a second antiviral agent. The second antiviral agent can be another compound of the present invention, but is preferably a different type of antiviral agent, such as a reverse transcriptase inhibitor, an integrase inhibitor, a fusion inhibitor or a protease inhibitor. The nucleoside analogue can be an AZT, a ddCTP or a ddI, for example, and the fusion inhibitor can be T-20, for example.</p><p id="p0018" num="0018">Because of their antiviral activity, in one embodiment of the present invention, the compounds of the present invention are useful for the manufacture of medicaments. These medicaments include formulations and compositions useful for the treatment of viral diseases affecting mammals, including humans. These medicaments are also useful for inhibiting the transmission of viral diseases from one mammal to another.</p><p id="p0019" num="0019">In another embodiment, the present invention provides methods for dissociating a metal ion from a zinc finger-containing protein, the method comprising the step of contacting the zinc finger with a compound of the present invention. In one aspect, the zinc finger is part of a viral protein, such as a nucleocapsid protein, a Gag protein or a Gag-Pol protein. The invention also provides methods for dissociating a metal ion from a zinc finger-containing<!-- EPO <DP n="6"> --> protein on an intact virus (<i>e.g.,</i> viral particle, virion). The contacting of the virus or viral protein with the compound can be performed in vitro or in vivo. In one aspect, the zinc finger comprises a retroviral protein, e. g., a virus from an avian sarcoma retroviral group, a mammalian B-type retroviral group, a human T cell leukemia retroviral group, a bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group or a lentivirus group. The retroviral protein can be derived from an HIV-1, an HIV-2, an SIV, a BIV, an EIAV, a Visna, a CaEV, an HTLV-1, a BLV, an MPMV, an MMTV, an RSV, an MuLV, a FeLV, a BaEV or an SSV retrovirus.</p><p id="p0020" num="0020">In yet another embodiment, the invention provides a method for detecting the presence of a zinc finger-containing protein, comprising the steps of contacting the zinc finger-containing protein with a compound of the present invention to dissociate a metal ion, usually zinc, and detecting the metal ion or detecting a change caused by its dissociation. In one aspect, detecting the dissociation of the metal ion from the zinc finger can be carried out using a method such as, for example, capillary electrophoresis, immunoblotting, nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), detecting release of radioactive zinc-65, detecting fluorescence or detecting a gel mobility shift.</p><p id="p0021" num="0021">The invention further provides a method for inactivating a virus, the method comprising contacting a virus with an effective amount of a composition comprising at least one compound of the present invention, wherein contacting the virus with the compound inactivates the virus. This inactivation can be partial (e. g., an attenuation) or complete. In one aspect, the compound of the present invention dissociates a zinc ion from a polypeptide, e. g., a zinc finger. The virus can be a retrovirus derived from an avian sarcoma or leukosis retroviral group, a mammalian B-type retroviral group, a human T cell leukemia or bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group or a lentivirus group. The retrovirus can be an HIV-2, an SIV, a BIV, an EIAV, a Visna, a CaEV, an HTLV-1, a BLV, an MPMV, an MMTV, an RSV, an MuLV, a FeLV, a BaEV or an SSV retrovirus. The retrovirus can also be an HIV-1 retrovirus.</p><p id="p0022" num="0022">The contacting of the virus with a composition comprising at least one compound of the invention is performed <i>in vitro.</i> The contacting of the virus with the compound or composition can be performed in or on any biological tissue, food, chemical or device, such as a blood product, blood plasma, tissue or organ for transplantation, nutrient<!-- EPO <DP n="7"> --> media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, bacteria, viruses, food, drink, implant, prosthesis and the like.</p><p id="p0023" num="0023">The present application discloses an isolated and inactivated virus, wherein the virus is inactivated by a method comprising contacting the virus with a compound of the present invention, wherein contacting the virus with the compound inactivates the virus. The present application further discloses a vaccine formulation comprising an inactivated virus. The inactivated virus can be a retrovirus, e. g., an avian sarcoma retroviral group, a mammalian B-type retroviral group, a human T cell leukemia retroviral group, a bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group or a lentivirus group. The isolated and inactivated virus can be an HIV-2, an SIV, a BIV, an EIAV, a Visna, a CaEV, an HTLV-1, a BLV, an MPMV, an MMTV, an RSV, an MuLV, a FeLV, a BaEV and an SSV retrovirus. The inactivated virus can also be an HIV-1.</p><p id="p0024" num="0024">In certain aspects, the invention provides a method of selecting a compound capable of dissociating a metal ion chelated with a zinc finger of a viral protein, the method comprising: (a) contacting the zinc finger with a compound of the present invention; and (b) detecting the dissociation of the metal ion from the zinc finger of the viral protein. The metal ion can be a zinc ion. The step of detecting the dissociation of the metal ion from the zinc finger can be carried out using a variety of analytical methods such as capillary electrophoresis, immune-blotting, nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), detecting release of radioactive zinc-65, detecting fluorescence, detecting gel mobility shift, or combinations of such methods.</p><p id="p0025" num="0025">The present application further discloses a kit for selecting a compound capable of dissociating a metal ion from a zinc finger of a protein, e. g., a viral protein, the kit comprising the protein, e. g., a retroviral protein, and instructions for detecting the dissociation of the metal ion from the viral protein, the instructions comprising directions for the selection of a compound of the present invention. In one aspect, a zinc ion is chelated with the zinc finger of the viral protein. In one aspect, the viral protein is incorporated in an intact virus, e. g., a retrovirus. The zinc finger can be derived from a virus, such as an avian sarcoma retroviral group, a mammalian B-type retroviral group, a human T cell leukemia retroviral group, a bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group or a lentivirus group. The zinc finger can be derived from a virus, e. g., an HIV-2, an SIV, a BIV, an EIAV, a Visna, a CaEV, an HTLV-1, a BLV, an MPMV, an MMTV, an RSV, an MuLV, a FeLV, a BaEV, or an SSV retrovirus. The zinc finger can also be derived from an HIV-1 virus. In alternative aspects of the kit disclosed,<!-- EPO <DP n="8"> --> the instructions are directed to detecting the dissociation of the metal ion from the protein using capillary electrophoresis, immune-blotting, nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), detecting release of radioactive zinc-65, detecting fluorescence or detecting a gel mobility shift. The kit can also be used for the detection of the presence of a zinc finger-containing viral protein.</p><p id="p0026" num="0026">The invention also provides a virucidal composition comprising a compound of the present invention. The virucidal composition can further comprise blood plasma, tissue or organs for transplantation, nutrient media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, bacteria, viruses, food, drink, implants, prostheses and the like. The present invention provides blood plasma, nutrient media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, bacteria, viruses, food, drink, implants, prostheses comprising a compound of the present invention.</p><p id="p0027" num="0027">The invention further provides a pharmaceutical formulation comprising a compound of the present invention. The pharmaceutical formulation can further comprise a pharmaceutically acceptable excipient, carrier, or diluent, and can also optionally include at least one additional antiviral agent.</p><p id="p0028" num="0028">The invention provides an array or a bead comprising a compound of the present invention.</p><p id="p0029" num="0029">The application discloses a kit for screening for the presence of anti-viral antibodies in a biological fluid comprising a polypeptide or a virion comprising a compound of the present invention. The application discloses a method for detecting the presence of an anti-viral antibody in a biological sample comprising the following steps: (a) providing a polypeptide or a virion comprising a compound of the present invention; (b) providing a biological sample; (c) contacting the biological sample with the polypeptide or virion of step (a); and, (d) detecting the presence of an antibody specifically bound to the polypeptide or virion, thereby detecting the presence of an anti-viral antibody in the biological sample. The biological sample can be any biological fluid, or a fluid comprising a biological material (e. g., from a biopsy sample). The biological fluid can be, e. g., a serum, tear, sputum, saliva, blood, urine, vaginal fluid, or a semen sample.</p><p id="p0030" num="0030">The details of one or more embodiments of the present invention are set forth in the accompanying drawings and the description below.<!-- EPO <DP n="9"> --></p><heading id="h0003"><b>BRIEF DESCRIPTION OF THE DRAWINGS</b></heading><p id="p0031" num="0031"><ul><li><figref idrefs="f0001">Figure 1</figref> depicts certain compounds of the present invention. Compound numbers in Table 1 and Table 2 herein, which describe the biological activity of these compounds, refer to the compound numbers in <figref idrefs="f0001">Figure 1</figref>.</li></ul></p><heading id="h0004"><b>DETAILED DESCRIPTION OF THE INVENTION</b></heading><p id="p0032" num="0032">The present invention provides novel compounds, compositions and methods of using these compounds and compositions, inter alia, to inactivate viruses. Certain compounds of the present invention are capable of interacting with zinc finger containing proteins. Because many viruses require zinc finger-containing proteins for activity, these compounds can inactivate a broad range of viruses that contain zinc finger motifs. This inactivation can be effected when the compound contacts the virus's nucleocapsid, or any other zinc finger-containing protein, or other sensitive component of the virus. However, the compositions of the present invention can inactivate a virus by a variety of mechanisms, including, but not limited to, covalent interaction with metal-ion-complexing zinc fingers, and the invention is not limited by any particular theory or mechanism of action.</p><p id="p0033" num="0033">In one embodiment, the present invention provides a compound as described above.<!-- EPO <DP n="10"> --></p><p id="p0034" num="0034"><figref idrefs="f0001">Figure 1</figref> illustrates the embodiments of the present invention.<!-- EPO <DP n="11"> --></p><p id="p0035" num="0035">Because of their antiviral activity, the compounds of this invention are useful for the manufacture of medicaments. These medicaments include formulations and compositions useful for the treatment of viral diseases affecting mammals, including humans. They are also useful for inhibiting the transmission of viral diseases from one host to another. Such medicaments typically include pharmaceutically acceptable excipients, fillers, and diluents, and may optionally include other active ingredients such as other antiviral agents.</p><p id="p0036" num="0036">The present invention also includes pharmaceutical compositions containing compounds of formula (I). These compositions may be pharmaceutical formulations, or they may be combinations of the compounds of the present invention with food, cosmetic, biological, or other items that benefit from treatment with an anti-retroviral agent.</p><p id="p0037" num="0037">The compositions of the present invention can be used to tag, attenuate or inactivate any organelle, cell or virus comprising a zinc finger-containing protein or other sensitive molecule. In one aspect of the invention, the compositions of the present invention inactivate retroviruses, such as, for example, HIV-1.</p><p id="p0038" num="0038">In one aspect, the compositions of the present invention are not affected (<i>i.e</i>., their activity is not greatly diminished in vivo) by the reducing environment of biological fluids. Thus, they would be effective as therapeutic agents in the treatment of viral, especially retroviral, infections. The virucidal action of the compositions of the present invention could be extracellular or intracellular. Thus, when used as systemic therapeutic agents, they could decrease (slow the rate of), or block, cell to cell transmission of virus and/or the expansion of reservoirs of latent virus. The virucidal activity of the compositions of the present invention is useful in <i>in vitro</i> applications, such as, e. g., making inactivated viruses to be used as, <i>e.g.,</i> reagents or vaccines, and as sterilizing reagents and topical microbicides.</p><p id="p0039" num="0039">Although the compositions, including the pharmaceuticals, of the invention are not limited by any particular mechanism or theory, they may selectively target highly conserved, mutationally intolerant viral components, such as the zinc finger region of nucleocapsid proteins. This effectively addresses problems of drug resistance. In addition, the compounds of the present invention may have the capacity to disable virus extracellularly during transit as well as intracellularly during early and late phases of the replication process. This renders them useful for inhibition or prevention of transmission of a viral infection from one host to another.<!-- EPO <DP n="12"> --></p><p id="p0040" num="0040">A"zinc finger"motif is a highly conserved and essential structure found in many viruses, including retroviruses. For example, Gag and Gag-Pol proteins in the Retroviridae, except for Sputnaviruses, contain a highly conserved zinc finger motif (CCHC, where C = cysteine and H = histidine) within the nucleocapsid p7 (NCp7) protein portion of the polyprotein (see definitions below). The absolute conservation of the metal chelating cysteine and histidine residues along with other residues of the protein, and the participation of NCp7 in essential functions during early and late phases of virus replication, identifies this feature as an especially appealing antiviral target. Mutations of the chelating residues in the zinc finger yield a non-infectious virus. Because these zinc fingers are identical in most retroviruses, certain compositions of the present invention that are able to inhibit their function may therefore function as broad spectrum antiviral therapeutic drugs, effective against HIV variants that have developed resistance to other antiviral agents.</p><p id="p0041" num="0041">As noted above, some compounds of the present invention can inactivate HIV-1. While not bound by any particular mechanism or theory, they may interact with HIV-1 nucleocapsid proteins. HIV-1's nucleocapsid (NC) protein, NCp7, contains two zinc fingers separated by only seven amino acid residues (see, e. g., <nplcit id="ncit0026" npl-type="s"><text>Henderson (1992) J. Virol. 66 : 1856</text></nplcit>). Both zinc fingers are essential for infectivity (<nplcit id="ncit0027" npl-type="s"><text>Aldovini (1990) J. Virol. 64: 1920</text></nplcit>;<nplcit id="ncit0028" npl-type="s"><text> Gorelick (1990) J. Virol. 64: 3207</text></nplcit>). Thus, the HIV-1 nucleocapsid is a particularly vulnerable target for zinc finger inactivating agents such as certain compounds of the present invention.</p><p id="p0042" num="0042">Because all evidence points toward complete conservation of the chelating residues and some other key residues within the fingers, the compounds of the present invention can be used as broad-spectrum antiviral agents. Mutation of any of the zinc finger residues results in loss, severe compromise or attenuation of virus infectivity. Even mutations that maintain metal ion-chelating properties of the fingers (CCHC to CCHH or CCCC, where C = cysteine and H = histidine), result in loss of infectivity. Thus, there is no known evidence for a pathway of single or multiple zinc finger mutations leading to restoration of the protein's activity.<!-- EPO <DP n="13"> --></p><p id="p0043" num="0043">Without being bound by any particular theory or mechanism of action, as part of an antiretroviral drug, the acylthiol linkage may provide a weakly reactive bond that promotes transfer of the acyl group to a nucleophilic target-site atom when the drug is bound in a favorable orientation in a binding site on a protein. This site can be a highly conserved component of a retrovirus, such as the zinc finger loops of the nucleocapsid protein, e. g., NCp7 of HIV-1. The target locus for covalent modification can be one or more cysteine side chains therein. The covalent interaction (acylation) at this site may result in essentially irreversible inactivation of the conserved target structure of the virus, serving to reduce its rate of replication in the host cell and, further, to disturb the pattern of packaging of the genomic RNA in either the budding or cell-free virion.</p><p id="p0044" num="0044">It has recently also been found that in certain compounds containing a free thiol group, the thiol group interacts with the NCp7 zinc finger. These thiol compounds can be given as antiviral agents, or they may be formed as a result of enzymepromoted or chemical hydrolysis of an acylthiol iri vivo, or they may form as a result of the acylation of a zinc finger by an acylthiol compound of the present invention. They may act as ligands displacing the normal chelating bonds between the finger loop cysteines and the central zinc ion. Zinc ions are not ejected in these cases, but resulting small shifts in conformation of the affected loop apparently disturb critical interactions with genomic RNA during the assembly of new viral particles. Thus, like the acylthiols, these free component thiol compounds are sometimes highly potent antivirals that are effective to prevent or treat viral infections.</p><p id="p0045" num="0045">Thiols, by their chemical nature, may not be the best chemotype to give directly as an antiviral drug, however. The pKa values for certain thiols can be as low as 5 to 6 for some aromatic thiols, for example. At physiological pH, such thiols exist substantially as negatively charged (thiolate) species. Their charge may impede absorption and passive membrane transmission. In addition, aromatic thiolates are highly nucleophilic and potentially reactive toward disulfide bonds and other electrophilic structures. For example, they can be employed in catalytic re-scrambling of mismatched cystines in proteins, much in the same manner as protein disulfide isomerase (PDI) which likewise possesses a low pKa thiol (a special cysteine side chain) in its active site (<nplcit id="ncit0029" npl-type="s"><text>Gough, J. Anaer. Chem. Soc. 124, 3885- 3892 (2002</text></nplcit>)).<!-- EPO <DP n="14"> --></p><p id="p0046" num="0046">Certain of the acylthiols of the present invention overcome these disadvantages possessed by their component thiols, by serving as prodrugs which modify the physical properties and metabolic susceptibility until the compound has time to reach its molecular target. Furthermore, certain acylthiol compounds of the present invention produce the inhibitory activity of a thiol compound <i>and</i> the covalent inactivation of an acylthiol compound. In these compounds, the acyl group may remain intact until the compound reaches a zinc finger protein. The compound then reacts with the zinc finger cysteine, transferring an acyl group onto the cysteine sulfur atom as described above. This inactivates one viral protein molecule, and releases a free thiol. The free thiol can then bind to a second zinc finger protein, resulting in a second inhibitory event. Therefore, certain acylthiol compounds operate by two distinct mechanisms, and can be considered simultaneously a drug and a prodrug.</p><p id="p0047" num="0047">For such compounds, it is advantageous that the <i>in vivo</i> hydrolysis rate be low enough so that most of the administered acylthiol compound reaches a zinc finger-containing protein before either chemical or enzymatic hydrolysis occurs. This allows it to acylate a first zinc finger protein and also, in the form of a free thiol compound, inhibit a second zinc finger protein. Therefore, slow <i>in vivo</i> hydrolysis is sometimes an advantage for acylthiol compounds of the present invention when used to treat retroviral infections, because slow hydrolysis increases the opportunity for the acylation of a zinc finger protein to occur before the acylthiol is hydrolyzed by other mechanisms operating within the host organism.</p><heading id="h0005"><b>I. Definitions</b></heading><p id="p0048" num="0048">To facilitate understanding the invention, a number of terms are defined below.</p><p id="p0049" num="0049">The term "halo" or "halogen" as used herein refers to fluorine, chlorine, bromine, or iodine.</p><p id="p0050" num="0050">As used herein, the term "alkyl", alone or in combination with other terms such as alkylamino, refers to refer a genus of radicals including branched and unbranched, saturated or unsaturated, monovalent hydrocarbon radicals, including substituted derivatives and equivalents thereof. In one aspect, the hydrocarbons have from 1 to about 20 carbons, and often preferably from 1 to about 10 carbons. When the alkyl group has from 1 to about 6 carbon atoms, it is referred to as a "lower alkyl." "Alkyl" groups also include alkyl chains optionally interrupted with one or two members, which may be the same or different, selected from the group consisting of a double bond, a triple bond, O, S, NR", C(O), and C(NR"), so<!-- EPO <DP n="15"> --> long as the alkyl group is attached through a carbon atom of its alkyl chain. R" on NR" or C(NR") may be H, acyl, lower alkyl, or alkoxy. Exemplary alkyl radicals include, e.g., structures containing one or more methylene, methine and/or methyne groups arranged in acyclic and/or cyclic forms. Branched structures having a branching motif similar to isopropyl, tert-butyl, isobutyl, 2-ethylpropyl, etc. are also included. As used herein, the term encompasses "substituted alkyls."</p><p id="p0051" num="0051">"Substituted alkyl" refers to alkyls as just described, containing one or more functional groups such as lower alkyl, aryl, acyl, halogen (i.e., alkylhalos, e.g., CF<sub>3</sub>), hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, arylamino, aryloxyalkyl, mercapto, thia, aza, oxo, alkoxycarbonyl, alkylaminocarbonyl, both saturated and unsaturated cyclic hydrocarbons, heterocycles and the like. The number of such groups that may be present is limited by the number of valences available on the alkyl group radical. These groups may be attached to any carbon of the alkyl moiety. Additionally, these groups may be pendent from, or integral to, the alkyl chain.</p><p id="p0052" num="0052">The term "alkylene" as used herein, either alone or in combination with other terms, refers to an alkyl group as described above which contains two unoccupied valences, and is hence a diradical. Such diradicals attach to two groups that will be specified, in addition to being optionally substituted as described above. "Alkylene-C(O)", for example, refers to an alkylene chain attached to a carbonyl group [C(O)] at one of its two unoccupied valences. This alkylene-C(O) group must attach to one group through an unoccupied valence of the alkyl chain portion of the alkylene, and to a second group through the unoccupied valence of the carbonyl carbon atom that occupies one of the two radical positions of the alkylene.</p><p id="p0053" num="0053">"Substituted alkylene" refers to alkylenes as just described, containing one or more functional groups such as lower alkyl, aryl, acyl, halogen (<i>i.e.,</i> alkylhalos, <i>e.g.,</i> CF<sub>3</sub>), hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, arylamino, aryloxyalkyl, mercapto, thia, aza, oxo, both saturated and unsaturated cyclic hydrocarbons, heterocycles and the like. The number of such groups that may be present is limited by the number of valences available on the alkylene group radical. These groups may be attached to any carbon of the alkylene moiety. Additionally, these groups may be pendent from, or integral to, the alkylene chain.</p><p id="p0054" num="0054">As used herein, the term "cycloalkyl", alone or in combination with other terms, refers to substantially carbocyclic rings of 3 to about 8 atoms, and includes fused, bridged, and spiro-fused ring systems, including bicyclic and tricyclic ring systems containing a total of up to about 16 ring atoms. Such cycloalkyl groups are optionally substituted, and the rings<!-- EPO <DP n="16"> --> are optionally interrupted with one or two members, which may be the same or different, selected from the group consisting of a double bond, a triple bond, O, S, NR", C(O), and C(NR"), where R" is H, optionally substituted alkyl or optionally substituted acyl, so long as the cycloalkyl group is attached through a carbon atom; no ring smaller than five ring atoms can include a double bond in the ring; and no ring smaller than about 7 atoms can include a triple bond within the ring.</p><p id="p0055" num="0055">"Substituted cycloalkyl" refers to cycloalkyls as just described, containing one or more functional groups such as lower alkyl, aryl, acyl, halogen (i.e., alkylhalos, <i>e.g.,</i> CF<sub>3</sub>), hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, arylamino, aryloxyalkyl, mercapto, thia, aza, oxo, both saturated and unsaturated cyclic hydrocarbons, heterocycles and the like. The number of such groups that may be present is limited by the number of valences available on the cycloalkyl group radical. These groups may be attached to any carbon of the cycloalkyl moiety. Additionally, these groups may be pendent from, or integral to, the cycloalkyl ring.</p><p id="p0056" num="0056">As defined herein the term "heteroalkyl", alone or in combination with other terms, refers to any alkyl group, as defined above, wherein one or more of its carbon atoms (other than the one which links the radical to other structures) is replaced by an atom of another element (a "heteroatom", <i>e.g.,</i> N, S, O, Si, P, etc.). It includes optionally substituted heteroalkyl groups.</p><p id="p0057" num="0057">The term "heterocycloalkyl" refers to a cyclic alkyl group possessing at least one heteroatom in its cyclic structure, and includes optionally substituted heterocycloalkyl groups.</p><p id="p0058" num="0058">The term "alkylamino" is used herein, either alone or in combination with other terms, to refer to the to the -NRR' group, which is attached through the N (nitrogen) atom, and where R and R' are H or optionally substituted lower alkyl, optionally substituted aryl, arylalkyl or substituted arylalkyl, wherein the alkyl, aryl, substituted aryl, arylalkyl and substituted arylalkyl groups are as described herein. Suitable alkylamino radicals include, for example, amino, methylamino, ethylamino, phenylamino, substituted phenylamino, benzylamino, phenethylamino, tert-butylamino, dimethylamino, pyrrolidino, morpholino, and the like.</p><p id="p0059" num="0059">The term "alkoxy" is used herein, either alone or in combination with other terms, to refer to the to the -OR group, which is attached through the O (oxygen) atom, and where R is a lower alkyl, substituted lower alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl, wherein the alkyl, aryl, substituted aryl, arylalkyl and substituted arylalkyl groups are as<!-- EPO <DP n="17"> --> described herein. Suitable alkoxy radicals include, for example, methoxy, ethoxy, phenoxy, substituted phenoxy, benzyloxy phenethyloxy, tert-butoxy, and the like.</p><p id="p0060" num="0060">The term "aryl" is used herein, either alone or in combination with other terms, to refer to an aromatic substituent that may be a single aromatic ring or multiple aromatic rings which are fused together, linked covalently, or linked to a common group such as a methylene or ethylene moiety. The common linking group may also be a carbonyl as in benzophenone. The aromatic ring(s) may include phenyl, naphthyl, biphenyl, fluroenyl, diphenylmethyl and benzophenone among others. The term "aryl" encompasses "arylalkyl."</p><p id="p0061" num="0061">"Substituted aryl" refers to aryl as just described and including one or more functional groups such as lower alkyl, acyl, halogen, alkylhalos (e.g., CF<sub>3</sub>), hydroxy, amino, alkoxy, alkylamino, acylamino, acyloxy, phenoxy, mercapto, each of which is optionally substituted. Both saturated and unsaturated cyclic hydrocarbons which are fused to the aromatic ring(s), linked covalently or linked to a common group such as a methylene or ethylene moiety are included. The linking group may also be a carbonyl such as in cyclohexyl phenyl ketone. The term "substituted aryl" encompasses "substituted arylalkyl."</p><p id="p0062" num="0062">As used herein the term "heteroaryl", either alone or in combination with other terms, refers to any aryl group, as defined above, wherein one or more of its ring atoms is replaced by a heteroatom (a "heteroatom", <i>e.g.,</i> N, S, O, etc). It includes bicyclic and tricyclic fused ring systems where each ring is aromatic and at least one of the aromatic rings contains a heteroatom. It further includes bicyclic and tricyclic ring systems where one or more of the rings is not aromatic, as long as at least one of the rings is an aromatic ring that contains a heteroatom.</p><p id="p0063" num="0063">"Substituted heteroaryl" refers to heteroaryl as just described and including one or more functional groups such as lower alkyl, acyl, halogen, alkylhalos (<i>e.g.,</i> CF<sub>3</sub>), hydroxy, amino, alkoxy, alkylamino, acylamino, acyloxy, phenoxy, mercapto, each of which is optionally substituted. Both saturated and unsaturated cyclic hydrocarbons which are fused to the heteroaromatic ring(s), linked covalently or linked to a common group such as a methylene or ethylene moiety are included. The linking group may also be a carbonyl such as in cyclohexyl pyridinyl ketone. The term "substituted heteroaryl" encompasses "substituted heteroarylalkyl."</p><p id="p0064" num="0064">The term "arylalkyl" is used herein, either alone or in combination with other terms, to refer to a subset of "aryl" in which the aryl group is further attached to an alkyl group, as defined herein.<!-- EPO <DP n="18"> --></p><p id="p0065" num="0065">The terms "array", "microarray", "DNA array", "nucleic acid array" and "biochip" are used interchangeably herein, and include all known variations of these devices.</p><p id="p0066" num="0066">"Contacting" refers to the act of bringing components of an interaction (<i>e.g.,</i> an inventive compound with a zinc finger protein or a viral protein) or a reaction into adequate proximity such that the interaction or reaction can occur. More generally, as used herein, the term "contacting" can be used interchangeably with the following: bound to, combined with, added to, mixed with, passed over, flowed over, etc.</p><p id="p0067" num="0067">As used herein, the term "Gag-Pol protein" refers to the polyprotein translation product of HIV-1 or other retroviruses, as described, <i>e.g.,</i> by <nplcit id="ncit0030" npl-type="s"><text>Fehrmann (1997) Virology 235: 352-359</text></nplcit>; <nplcit id="ncit0031" npl-type="s"><text>Jacks (1988) Nature 331: 280-283</text></nplcit>. The "Gag protein" is processed by a viral protease to yield mature viral proteins, see, <i>e.g.,</i> <nplcit id="ncit0032" npl-type="s"><text>Humphrey (1997) Antimicrob. Agents &amp; Chemotherapy 41: 1017-1023</text></nplcit>; <nplcit id="ncit0033" npl-type="s"><text>Karacostas (1993) Virology 193: 661-671</text></nplcit>.</p><p id="p0068" num="0068">As used herein, "isolated", when referring to a molecule or composition, such as, for example, a compound of the present invention, a compound bound to a polypeptide, a polypeptide-RNA complex or a virus, or a compound-inactivated virus, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids, etc., or other contaminants with which it is associated in vivo or in its naturally occurring state. In the context of compounds made by synthetic means, an isolated composition also includes a partially, or substantially, purified preparation containing the active ingredient. Thus, a compound, polypeptide or virion is considered isolated when it has been separated from any other component with which it is naturally associated, <i>e.g.,</i> cell membranes, as in a cell extract, serum, and the like. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry state or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-PAGE) or high performance liquid chromatography (HPLC).</p><p id="p0069" num="0069">As used herein, the term "nucleocapsid protein" or "NC protein" refers to the retroviral nucleocapsid protein, which is an integral part of the virion nucleocapsid where it coats the dimeric RNA genome, as described by <nplcit id="ncit0034" npl-type="s"><text>Huang (1997) J Virol. 71: 4378-4384</text></nplcit>;<!-- EPO <DP n="19"> --> <nplcit id="ncit0035" npl-type="s"><text>Lapadat-Tapolsky (1997) J. Mol. Biol. 268: 250-260</text></nplcit>. HIV-1's nucleocapsid protein is termed "NCp7, "see also<nplcit id="ncit0036" npl-type="s"><text> Demene (1994) Biochemistry 33: 11707-11716</text></nplcit>.</p><p id="p0070" num="0070">The term "retrovirus" as used herein refers to viruses of the Retroviridae family. These viruses can have ssRNA transcribed by reverse transcriptase, as described by, <i>e.g.,</i> <nplcit id="ncit0037" npl-type="b"><text>P. K. Vogt, "Historical introduction to the general properties of retroviruses". In Retroviruses, eds. J. M. Coffin, S. H. Hughes and H. E. Varmus, Cold Spring Harbor Laboratory Press, 1997, pp. 1-26</text></nplcit>; <nplcit id="ncit0038" npl-type="b"><text>Murphy et al. (eds.) Archives of Virology/Supplement 10, 586 pp. (1995) Springer Verlag, Wien, NY</text></nplcit>. For a general description of the Retroviridae family, see the Committee on International Taxonomy of Viruses, Virology Division of the International Union of Microbiology Societies viral classifications and taxonomy. Retroviridae family members containing zinc finger motif-containing polypeptides and whose activity, e. g., replication or infectivity, can be inhibited by the compounds of the present invention include, e. g. , avian sarcoma and leukosis retroviruses (alpharetroviruses), mammalian B-type retrovinuses (betaretroviruses) (e. g. , mouse mammary tumor virus), human T-cell leukemia and bovine leukemia retroviruses (deltaretroviruses) (e. g. , human T-lymphotropic virus 1), murine leukemia-related group (gammaretroviruses), D-type retroviruses (epsilonretroviruses (e. g. , Mason-Pfizer monkey virus), and lentiviruses. Lentiviruses include, e. g. , bovine, equine feline, ovine/caprine, and primate lentivirus groups, such as human immunodeficiency virus type 1 (HIV-1). Examples of particular species of viruses whose replicative capacity inactivated by the compounds of the present invention include HIV-1, HIV-2, SIV, BIV, EIAV, Visna, CaEV, HTLV-1, BLV, MPMV, MMTV, RSV, MuLV, FeLV, BaEV, and SSV retroviruses.</p><p id="p0071" num="0071">As used herein, the term "acylthiol" refers to a chemical structure, G-S- (C=X)-G', wherein G and G'represent any two groups except that G usually joins to the sulfur atom (S in the-2 oxidation state) through a C-S bond, while G'may join to the'C=X'carbon via a C C bond, a C-0 bond, a C-S bond, or a C-N bond. X represents O, S, or NR", where R"is H, alkyl, hydroxy, or alkoxy.</p><p id="p0072" num="0072">As used herein, the terms "thiolester" and "thioester" may be used interchangeably, and they refer to a chemical structure, G-S- (C=O)-G', wherein G and G' represent any two groups except that G usually joins to the sulfur atom (S in the-2 oxidation state) through a C-S bond and G' must join to the carbonyl carbon via a C-C bond. These thioesters are acylthiols and the preferred embodiments of the present invention.</p><p id="p0073" num="0073">As used herein, the term "zinc finger" refers to a polypeptide motif consisting of cystines and/or histidines that coordinate metal ions giving rise to structures involved in<!-- EPO <DP n="20"> --> protein/nucleic acid and/or protein/protein interactions. The compounds of the present invention are capable of modifying the structure of zinc finger peptides in such a way that allows eventual dissociation of the metal ions. Typically, the metal ion is a divalent cation, such as those of zinc or cadmium. A zinc finger motif-containing protein is commonly a highly conserved and essential structure in viruses. Zinc finger motifs are found in human papilloma virus (HPV), particularly, HPV E6 and E7 proteins (see, e.g., <nplcit id="ncit0039" npl-type="s"><text>Ullman (1996) Biochem. J. 319: 229-239</text></nplcit>), influenza virus (see, e.g.,<nplcit id="ncit0040" npl-type="s"><text> Nasser (1996) J. Virol. 70: 8639-8644</text></nplcit>). In most subfamilies of Retroviridae, including avian sarcoma and leukosis retroviruses, mammalian B-type retroviruses, human T-cell leukemia and bovine leukemia retroviruses, D-type retroviruses, and lentiviruses, the invariable zinc finger motif is the most highly conserved structure. Retroviral nucleocapsid, Gag and Gag-Pol proteins have zinc finger motifs. In retroviruses, the zinc finger motif typically consists of 14 amino acid residues, with four residues being invariant, one exemplary zinc finger motif is described as Cys(X)2Cys(X)4His(X)4Cys and is referred to as a "CCHC zinc finger" (<nplcit id="ncit0041" npl-type="s"><text>Henderson (1981) J. Biol. Chem. 256: 8400</text></nplcit>). Zinc fingers chelate zinc through their histidine imidazole and cysteine thiolates (<nplcit id="ncit0042" npl-type="s"><text>Berg (1986) Science 232: 485</text></nplcit>;<nplcit id="ncit0043" npl-type="s"><text> Bess (1992) J. Virol. 66: 840</text></nplcit>;<nplcit id="ncit0044" npl-type="s"><text> Chance (1992) Proc. Natl. Acad. Sci. U.S.A. 89: 10041</text></nplcit>; <nplcit id="ncit0045" npl-type="s"><text>South (1990) Adv. Inorg. Biochem. 8: 199</text></nplcit>; <nplcit id="ncit0046" npl-type="s"><text>South (1990) Biochem. Pharmacol. 40: 123-129</text></nplcit>). CCHC zinc fingers perform essential functions in retroviral infectivity, such as packaging genomic RNA. They are also essential for early events in virus infection.</p><p id="p0074" num="0074">As used herein, the term "antiviral activity" means a compound has demonstrated some degree of antiviral activity in any assay, e.g., the XTT cytoprotection assay or p24 ELISA assays. As used herein, the term "virucidal" includes any degree of viral attenuation, including, but not limited to, complete inactivation or killing of a virus.</p><p id="p0075" num="0075">As used herein, terms such as "viral infectivity" or "index of infectivity" refers to the capacity of virus to pass from an infected cell to an uninfected cell, bringing about productive infection of the uninfected cell. For example, measurements of infectivity may be carried out by the MAGI assay, wherein the uninfected recipient cells are Hela CD4 HIV LTR Gal cells.</p><p id="p0076" num="0076">As used herein, the terms "inhibit the transmission of the virus" and "antiviral activity" mean the ability of a compound to negatively affect viral replicative capacity in any way. Such inhibition of transmission, <i>e.g.,</i> loss in replicative capacity can be measured using any means known in the art. For example, a compound is inhibiting the transmission of the virus (having antiviral activity) if it diminishes a virus' ability to produce progeny, (when in the form of a virion) fuse with a cell, enter a cell, bud from a cell, survive intracellularly or<!-- EPO <DP n="21"> --> extracellularly, reverse transcribe its RNA genome, translate viral proteins, process polyproteins with proteases, effect intracellular assembly of viral components into a capsid, and the like. The ability of a compound of the present invention to inhibit the transmission of a virus is not limited by any chemical or biological mechanism or pathway. A compound can inhibit infectivity or transmission (decrease replicative capacity) of a virus by, e.g.: binding to a nucleocapsid protein, such as NCp7; preventing binding of NCp7 to viral RNA or another nucleic acid; being involved in a specific chemical attack resulting in a stable or transient adduct; promoting the formation of inter- and intramolecular disulfide bonds through consequent destabilization of the NCp7 zinc finger loops; interacting with other conserved or non-conserved residues within the NCp7 protein which results in loss of function; and the like.</p><p id="p0077" num="0077">Unless otherwise defined, terms used herein are intended to have the meaning that would be understood by a person of ordinary skill in the art for that term in its instant context.</p><heading id="h0006"><b>II. Compounds and Methods of Synthesis</b></heading><p id="p0078" num="0078">The present invention provides novel compounds for inactivating viruses, such as retroviruses. The skilled artisan will recognize that the compounds of the present invention can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, e.g., <nplcit id="ncit0047" npl-type="b"><text>Organic Syntheses Collective Volumes, Gilman et al. (Eds), John Wiley &amp; Sons, Inc., NY</text></nplcit>; <nplcit id="ncit0048" npl-type="s"><text>Venuti (1989) Pharm. Res. 6: 867-873</text></nplcit>; the <nplcit id="ncit0049" npl-type="b"><text>Beilstein Handbook of Organic Chemistry (Beilstein Institut fuer Literatur der Organischen Chemie, Frankfurt, Germany</text></nplcit>); Beilstein online database and references obtainable therein. The invention can be practiced in conjunction with any method or protocol known in the art, which is well described in the scientific and patent literature. Therefore, only a few general techniques will be mentioned prior to presenting specific methodologies and examples relative to the novel acylthiols and methods of the present invention.</p><p id="p0079" num="0079">Organic reagents and intermediates can be obtained from, e.g., Sigma/ Aldrich/ Fluka (St. Louis, MO; Milwaukee, WI), Fisher/Acros (Raleigh, NC) and Lancaster Synthesis, Inc. (Windham, NH). Solvents and other chemicals were reagent grade. Structure and composition of all compounds were verified by <sup>1</sup>H NMR and, when necessary, by EI MS, and analyzed by silica layer TLC, eluting with chloroform-methanol mixtures and viewing with UV light. Isolation and purification of reaction products were accomplished by standard techniques, which would be obvious to one of ordinary skill in the art.<!-- EPO <DP n="22"> --></p><p id="p0080" num="0080">Compounds of the present invention can be synthesized by combining reactions known to persons of ordinary skill in the art of chemical synthesis. Reactions specifically useful for preparing compounds of this invention are described in <nplcit id="ncit0050" npl-type="s"><text>Bioorg Med. Chem. 10, 1263-73 (2002</text></nplcit>) and <nplcit id="ncit0051" npl-type="s"><text>J. Med. Chem. 42, 67-86 (1999</text></nplcit>). The general scheme used to prepare these compounds consists of the preparation of an aryl carboxylic acid disulfide compound of formula (II).
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="70" he="33" img-content="chem" img-format="tif"/></chemistry></p><p id="p0081" num="0081">Many such compounds and the methods for their preparation are well known to those of skill in the art. The benzoic acid moieties are activated by methods well known in the art, and are used to acylate amine compounds of formula (III). Methods for such activation include formation of acyl halides, such as acyl chlorides, and activated esters, such as Nacyloxysuccinimides. Also, many other methods for dehydratively forming amide bonds from an amine and a carboxylic acid are known, including coupling with reagents such as dialkyl carbodiimides.
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="49" he="28" img-content="chem" img-format="tif"/></chemistry></p><p id="p0082" num="0082">Many compounds of formula (III) are known, and methods for preparation of compounds of formula (III) are well known to persons of skill in the art.</p><p id="p0083" num="0083">Where appropriate, reactive functional groups other than the amine which is intended to react with the activated benzoic acid group can be protected to prevent undesired side reactions. Methods for selecting, attaching, and removing such protecting groups are well known to those of ordinary skill in the art, and are described, for example, in <nplcit id="ncit0052" npl-type="b"><text>Peter Wut's and Theodora Greene's book, Protective Groups in Organic Synthesis (1999</text></nplcit>).</p><p id="p0084" num="0084">Acylation of compound (III) produces a disulfide of formula (IV), which is reduced to produce the free thiol compound of formula (V), for example, using TCEP-HCl (tris (2carboxyethyl) phosphine hydrochloride).<!-- EPO <DP n="23"> --></p><p id="p0085" num="0085">Compounds of formula (V) are the component thiol compounds of the present invention, and can optionally be acylated with a wide variety of active acylating agents to produce the acylthiol compounds of formula (I = J-K-Q-NR<sup>1</sup>R<sup>2</sup>). The required acylating agents are well known, and conditions for such acylations are obvious to those of ordinary skill in the art.
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="121" he="62" img-content="chem" img-format="tif"/></chemistry></p><p id="p0086" num="0086">The preferred compounds of the present invention are set forth in <figref idrefs="f0001">Figure 1</figref>.</p><heading id="h0007"><b>III. Compositions</b></heading><p id="p0087" num="0087">The invention provides a composition comprising a bio-organic, inorganic or other material and an amount of one or more compounds of the present invention effective to inactivate or attenuate a viral protein or a virion that comes in contact with the material, <i>e.g.,</i> a virus contaminating the material. The material can be bio-organic, such as, <i>e.g.,</i> blood plasma, nutrient media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, bacteria, viruses, foods, drinks. They can be surgical or other medical materials, such as, <i>e.g.,</i> implant materials or implantable devices (<i>e.g.,</i> plastics, artificial heart valves or joints, collagens), prostheses, medical materials (<i>e.g.,</i> tubing for catheterization, intubation, IVs) and containers (<i>e.g.,</i> blood bags, storage containers), and the like. The preferred compounds for incorporation in compositions of this invention are set forth in <figref idrefs="f0001">Figure 1</figref>.</p><heading id="h0008"><b>A. Virucidals</b></heading><p id="p0088" num="0088">A compound of the present invention can be in the form of a composition that is applied to any of the above materials as a virucidal reagent and removed before the material's use. The virucidal composition can contain a mixture of different compounds of the present<!-- EPO <DP n="24"> --> invention in varying amounts. For example, compounds of the present invention can be added to cell cultures to reduce the likelihood of viral contamination, providing added safety for the laboratory workers.</p><heading id="h0009"><b>B. Pharmaceutical Formulations</b></heading><p id="p0089" num="0089">The invention provides pharmaceutical formulations comprising one or more of the compounds of the present invention. The compounds of the present invention can be used in pharmaceutical compositions that are useful for administration to mammals, particularly humans, for the treatment of viral infections, especially retroviral, infections. The compounds of the present invention may be formulated alone or in combination with other pharmacologically active ingredients. Of special interest are formulations including a second antiviral agent such as, for example, nucleoside analogs, nucleotide analogs, reverse transcriptase inhibitors, integrase inhibitors, fusion inhibitors and protease inhibitors that are active against retroviruses such as HIV.</p><p id="p0090" num="0090">The compounds of the present invention can be formulated as pharmaceuticals for administration in a variety of ways. Typical routes of administration include both enteral and parenteral. These include, <i>e.g.,</i> without limitation, subcutaneous, intramuscular, intravenous, intraperitoneal, intramedullary, intrapericardiac, intrabursal, oral, sublingual, ocular, nasal, topical, transdermal, transmucosal, vaginal or rectal. The mode of administration can be, <i>e.g.,</i> via swallowing, inhalation, injection or topical application to a surface (<i>e.g.,</i> eyes, mucous membrane, skin). Particular formulations typical and appropriate for specific modes of administration are familiar to those of skill in the art. Various contemplated formulations include, <i>e.g.,</i> aqueous solution, solid, aerosol, liposomal and transdermal formulations. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, <i>e.g.,</i> the <nplcit id="ncit0053" npl-type="b"><text>latest edition of "Remington's Pharmaceutical Sciences" (Maack Publishing Co, Easton PA</text></nplcit>).</p><heading id="h0010"><b>1. Aqueous Solutions for Enteral, Parenteral Or Transmucosal Administration</b></heading><p id="p0091" num="0091">Examples of aqueous solutions that can be used in formulations for enteral, parenteral or transmucosal drug delivery include, <i>e.g.,</i> water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like. The formulations can contain pharmaceutically acceptable auxiliary substances to enhance stability, deliverability or solubility, such as buffering agents, tonicity adjusting agents, wetting agents,<!-- EPO <DP n="25"> --> detergents and the like. Additives can also include additional active ingredients such as bactericidal agents, or stabilizers. For example, the solution can contain sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate. These compositions can be sterilized by conventional, well-known sterilization techniques, or can be sterile filtered. The resulting aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.</p><p id="p0092" num="0092">Aqueous solutions are appropriate for injection and, in particular, for intravenous injection. The intravenous solution can include detergents and emulsifiers such as lipids. Aqueous solutions also are useful for enteral administration as tonics and administration to mucous or other membranes as, e.g., nose or eye drops. In exemplary preparations, the composition can contain a compound in an amount of about 1 mg/ml to 100 mg/ml, or, about 10 mg/ml to about 50 mg/ml.</p><heading id="h0011"><b>2. Formulations For Enteral Or Transdermal Delivery</b></heading><p id="p0093" num="0093">Solid formulations can be used for enteral administration. They can be formulated as, <i>e.g.,</i> pills, tablets, powders or capsules. For solid compositions, conventional nontoxic solid carriers can be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally from about 5%-95% of active ingredient, preferably from about 10% to about 60% active ingredient.</p><p id="p0094" num="0094">An exemplary non-solid formulation is for enteral (oral) administration. The carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. See <patcit id="pcit0002" dnum="US5494936A"><text>Sanchez, et al., U.S. Patent No. 5,494,936</text></patcit>. Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. Nonionic block copolymers synthesized from ethylene oxide and propylene oxide can also be pharmaceutical excipients; copolymers of this type can act as emulsifying, wetting, thickening, stabilizing, and dispersing agents, see, <i>e.g.,</i> <nplcit id="ncit0054" npl-type="s"><text>Newman (1998) Crit. Rev. Ther. Drug Carrier Syst. 15:89-142</text></nplcit>.<!-- EPO <DP n="26"> --></p><p id="p0095" num="0095">An exemplary unit dosage form, such as a tablet, can be between about 50 mg/unit to about 2 grams/unit, preferably between about 100 mg/unit to about 1 gram/unit.</p><heading id="h0012"><b>3. Topical Administration: Transdermal/ Transmucosal Delivery</b></heading><p id="p0096" num="0096">Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, e.g., intra-vaginal or intra-rectal administration, penetrants appropriate to the barrier to be permeated can be used in the formulation. Such penetrants are generally known in the art, and include, <i>e.g.,</i> for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents can be used to facilitate permeation. Transmucosal administration can be through nasal sprays, for example, or using suppositories. For topical administration, the agents are formulated into ointments, creams, salves, powders and gels. In one embodiment, the transdermal delivery agent can be DMSO. Transdermal delivery systems can also include, <i>e.g.,</i> patches.</p><p id="p0097" num="0097">The compounds can also be administered in sustained delivery or sustained release mechanisms, which can deliver the formulation internally. For example, biodegradeable microspheres or capsules or other biodegradeable polymer configurations capable of sustained delivery of a composition can be included in the formulations of the present invention (see, <i>e.g.,</i> <nplcit id="ncit0055" npl-type="s"><text>Putney (1998) Nat. Biotechnol. 16:153-157</text></nplcit>).</p><heading id="h0013"><b>4. Formulation for Delivery By Inhalation</b></heading><p id="p0098" num="0098">For inhalation, the formulated compound of the present invention can be delivered using any system known in the art, including dry powder aerosols, liquids delivery systems, air jet nebulizers, propellant systems, and the like. See, <i>e.g.,</i> <nplcit id="ncit0056" npl-type="s"><text>Patton (1998) Biotechniques 16:141-143</text></nplcit>; inhalation delivery systems by, <i>e.g.,</i> Dura Pharmaceuticals (San Diego, CA), Aradigm (Hayward, CA), Aerogen (Santa Clara, CA), Inhale Therapeutic Systems (San Carlos, CA), and the like. For example, the pharmaceutical formulation can be administered in the form of an aerosol or mist. For aerosol administration, the formulation can be supplied in finely divided form along with a surfactant and propellant. The surfactant preferably is soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol, and the polyoxyethylene and polyoxypropylene derivatives of these esters. Mixed esters, such as mixed or natural<!-- EPO <DP n="27"> --> glycerides can be employed. The surfactant can constitute 0.1%-20% by weight of the composition, preferably 0.25%-5%. The balance of the formulation is ordinarily propellant.</p><p id="p0099" num="0099">Liquefied propellants are typically gases at ambient conditions, and are condensed under pressure. Among suitable liquefied propellants are the lower alkanes containing up to 5 carbons, such as butane and propane; and preferably fluorinated or fluorochlorinated alkanes. Mixtures of the above can also be employed. In producing the aerosol, a container equipped with a suitable valve is filled with the appropriate propellant, containing the finely divided compounds and surfactant. The ingredients are thus maintained at an elevated pressure until released by action of the valve. See, e. g., <nplcit id="ncit0057" npl-type="s"><text>Edwards (1997) Science 276: 18681871</text></nplcit>. An exemplary nebulizer or aerosolizer device for administering compounds of this invention typically delivers an inhaled dose of about 1 mg/m3 to about 50 mg/m3. Delivery by inhalation is particular effective for delivery to respiratory tissues for the treatment of respiratory conditions including an inflammatory component.</p><heading id="h0014"><b>5. Other Formulations</b></heading><p id="p0100" num="0100">In preparing pharmaceuticals of the present invention, a variety of formulation modifications can be used and manipulated to alter pharmacokinetics and biodistribution. A number of methods for altering pharmacokinetics and biodistribution are known to one of ordinary skill in the art. For a general discussion of pharmacokinetics, See, <nplcit id="ncit0058" npl-type="b"><text>Remington's Pharmaceutical Sciences, supra, Chapters 37-39</text></nplcit>.</p><heading id="h0015"><b>IV. Methods of Use</b></heading><p id="p0101" num="0101">The compounds and compositions of the present invention can be used to treat or prevent viral infections. They are also useful for the inactivation of viruses, and such inactivated viruses are useful as vaccines, for example, or for the production or detection of antibodies. The compounds are also useful for detecting viruses containing zinc finger proteins, and for other purposes. The preferred compounds for use in the following methods are set forth in <figref idrefs="f0001">Figure 1</figref>.</p><heading id="h0016"><b>A. Use as Pharmaceuticals</b></heading><p id="p0102" num="0102">The compounds of the present invention are used for the treatment and prevention of viral infection, particularly, retroviral infections. The amount of compound adequate to accomplish this is defined as a "therapeutically effective dose". The dosage schedule and amounts effective for this use, <i>i.e.,</i> the "dosing regimen", will depend upon a variety of<!-- EPO <DP n="28"> --> factors, including frequency of dosing, the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration. The dosage regimen must also take into consideration the pharmacokinetics, <i>i.e.,</i> the compound's rate of absorption, bioavailability, metabolism, clearance, and the like (see, <i>e.g.;</i> the latest Remington's edition, supra).</p><p id="p0103" num="0103">Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. The administrations provide an amount of a compound of the present invention sufficient to treat the patient effectively. The total effective amount of a compound of the present invention can be administered to a subject as a single dose, either as a bolus or by infusion over a relatively short period of time, or it can be administered using a fractionated treatment protocol, in which the multiple doses are administered over a more prolonged period of time. One skilled in the art would know that the concentration of a compound of the present invention required to obtain an effective dose in a subject depends on many factors including, <i>e.g.,</i> the pharmacokinetics, possible hydrolysis products, the age and general health of the subject, the route of administration, the number of treatments to be administered and the judgment of the prescribing physician. In view of these factors, the skilled artisan would adjust the dose so as to provide an effective dose for a particular use.</p><heading id="h0017"><b>B. Inactivated Viruses as Vaccines</b></heading><p id="p0104" num="0104">The compounds of the present invention can be used to inactivate viruses, <i>e.g.,</i> retroviruses, such as HIV-1. In one aspect, the compounds of the present invention act by covalently attacking a nucleocapsid zinc finger, leading to disorganization of these structures and ejection of coordinated zinc ions. It will be readily apparent to those of skill in the art that once inactivated, a virus, e. g., a retrovirus, can be used, for example, as a vaccine or an immune stimulator, as a prophylactic, or as components in standard ELISA assays for the diagnosis of retroviral infections. Making use of these novel compositions and methods can involve incorporating a variety of standard procedures and reagents.</p><p id="p0105" num="0105">The invention may provide an isolated and inactivated virus, where the virus is inactivated by a method comprising contacting the virus with a compound of the present invention, wherein contacting said virus with said compound inactivates said virus. The isolated and inactivated virus further may comprise a vaccine formulation. A<!-- EPO <DP n="29"> --> vaccine formulation can also comprise an isolated complex of a viral protein or peptide with a compound of the present invention.</p><p id="p0106" num="0106">Complexed, inactivated viruses may be used in vaccine formulations that are useful for administration to mammals, <i>e.g.,</i> humans, to treat and generate immunity to of a variety of viral diseases, particularly retroviral infections, such as HIV-1. The vaccine formulations can be given single administrations or a series of administrations. When given as a series, inoculations subsequent to the initial administration are given to boost the immune response and are typically referred to as booster inoculations.</p><p id="p0107" num="0107">The vaccines may contain as an active ingredient an immunogenically effective amount of a compound-complexed, inactivated, virus. Useful carriers are well known in the art, and include, e. g. , thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly (D-lysine: D-glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are also advantageously used to boost an immune response.</p><heading id="h0018"><b>C. Other Uses of Inactivated Viruses and Proteins Complexed to Compounds of the Present Invention</b></heading><p id="p0108" num="0108">In addition to uses as vaccines, inactivated viruses and viral proteins complexed to compounds of the present invention have a variety of other uses. For example, complexed viral proteins or inactivated viruses can be used as reagents for the detection of corresponding anti-viral antibodies. A very commonly used test to determine if an individual is infected with a virus, such as HIV, is to screen for the presence of antiviral antibodies. In one aspect of the invention, a compound-inactivated virion or complexed viral protein is used in these detection tests to, e. g., trap and detect antigens or control antigens. See, <i>e.g.,</i> <nplcit id="ncit0059" npl-type="s"><text>Hashida (1997) J. Clin. Lab. Anal. 11: 267-286</text></nplcit>; <nplcit id="ncit0060" npl-type="s"><text>Flo (1995) Eur. J. Clin. Microbiol. Infect. Dis. 14: 504-511</text></nplcit>.</p><p id="p0109" num="0109">In alternative aspects of the invention, the inactivated virion or complexed viral protein is a crystallization reagent for X-ray crystallographic analysis or other ultrastructural studies, see, <i>e.g.,</i> <nplcit id="ncit0061" npl-type="s"><text>Yamashita (1998) J. Mol. Biol. 278: 609-615</text></nplcit>;<nplcit id="ncit0062" npl-type="s"><text> Wu (1998) Biochemistry 37: 4518-4526</text></nplcit>. In alternative aspects of the invention, they are used as molecular weight, pI or other controls in various physicochemical experiments and methodologies.<!-- EPO <DP n="30"> --></p><heading id="h0019"><b>D. Kits and Apparatus</b></heading><p id="p0110" num="0110">In an additional aspect, the present invention may provide kits embodying the methods and apparatus herein. Kits may comprise one or more compounds or compositions of the present invention, and, they optionally comprise one or more of the following: instructions for practicing the methods described herein, and/or for using the compound or composition; one or more assay components; a container for holding the compound, assay components, or apparatus components useful for manipulating compounds or practicing the methods herein, and/or, packaging materials.</p><p id="p0111" num="0111">In a further aspect, the present invention may provide for the use of any compound, apparatus, apparatus component or kit herein, for the practice of any method or assay herein, and/or for the use of any apparatus or kit to practice any assay or method herein.</p><p id="p0112" num="0112">In a further aspect, the present invention provides for the use of any compound, composition, virus, inactivated virus or viral component, cell, cell culture, mammal, apparatus, apparatus component or kit of the present invention, for the practice of any method or assay herein, and/or for the use of any apparatus or kit to practice any assay or method herein and/or for the use of viruses, cells, cell cultures, compositions or other features herein as a medicament. The manufacture of all components herein as medicaments for the treatments described herein is also provided and apparent upon review of the foregoing.</p><heading id="h0020"><b>E. Detecting the Dissociation of a Metal ion from a Zinc Finger Motif</b></heading><p id="p0113" num="0113">The invention may provide methods and kits to select compounds capable of dissociating a divalent ion chelated with a zinc finger motif. The motif can be an isolated peptide or polypeptide, or, it can be a substructure of a viral protein or a virion. The method includes contacting the zinc finger with a compound of the present invention, preferably an acylthiol, and subsequently detecting the dissociation of the metal ion from the zinc finger protein. The cation is commonly zinc. Any methodology known in the art can be used to detect the dissociation of the metal ion. Exemplary means include, <i>e.g.,</i> capillary electrophoresis, immune-blotting, nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), detecting release of radioactive zinc-65, detecting fluorescence, or detecting gel mobility shift, and other techniques which would be apparent to one of skill upon review of this disclosure. These procedures can be practiced with any protocol known<!-- EPO <DP n="31"> --> in the art, which are well described in the scientific and patent literature. A few exemplary techniques are set forth below.</p><p id="p0114" num="0114">As the invention provides novel compounds capable of dissociating a metal ion from a zinc finger in vitro, detection of the dissociation of the metal ion identifies some of the compounds within the scope of the present invention. For example, a zinc ejection assay can be used as a screen to identify compounds within the scope of the present invention. One strategy for such screening uses the XTT cytoprotection assay to monitor anti-viral activity. Alternative strategies use a Trp37 zinc ejection assay (see, <i>e.g.,</i> <patcit id="pcit0003" dnum="US6046228A"><text>U. S. Patent No. 6,046, 228</text></patcit>) or a N-propyl gallate (NPG) fluorescence zinc ejection assay to identify compounds of the present invention that are able to act at the cellular level, <i>e.g.,</i> on the NCp7 protein or its Gag or Gag-Pol precursors.</p><p id="p0115" num="0115">Certain compounds within the scope of the invention are capable of ejecting zinc from a zinc finger at some measurable rate The rate of this effect is not necessarily indicative of potency for antiviral activity, however. Compounds which eject zinc slowly, <i>i.e.,</i> with slow kinetics, are preferable for some uses, especially for certain <i>in vivo</i> applications. A "weak cation ejector" compound of the present invention would have a zinc ejection rate of about 0.86 RFU/min, or lower, as measured by the Trp37 zinc finger fluorescence assay. A "high" ejection rate would be in the range of approximately 8 RFU/min, or higher.</p><heading id="h0021"><b>1. Capillary Zone Electrophoresis (CZE)</b></heading><p id="p0116" num="0116">Retroviral zinc finger proteins complex with two zinc ions, each with a formal charge of 2+. Reagents that react with the protein and remove the zinc ions cause a change in the conformation and charge of the protein. Thus, the electrophoretic mobility of the reacted protein will differ from the mobility of the unreacted protein. Changes in electrophoretic mobility of the protein can easily be detected by the standard technique of capillary zone electrophoresis (CZE). For a general description of CZE, see, <i>e.g.,</i><nplcit id="ncit0063" npl-type="b"><text> Capillary Electrophoresis, Theory and Practice (Academic Press, Inc. Grossman and Colburn (eds.) (1992</text></nplcit>). Capillary zone electrophoresis has the advantage of simple automation, since many different samples can be loaded and analyzed in successive runs. Each run requires about 10 minutes and each sample tube can be analyzed multiple times. An exemplary kit utilizing CZE for analysis of compounds to be screened for CCHC zinc finger reactivity can contain about 100 u. g of purified retroviral NC protein complexed with zinc in, for example, 1.0 ml of water; this could be used for the testing of approximately 1000 test compounds.<!-- EPO <DP n="32"> --></p><heading id="h0022"><b>2. Release Of Radioactive Zinc From Zinc-65 Labeled NCp7</b></heading><p id="p0117" num="0117">Another exemplary screening method of the invention measures release of radioactive zinc from zinc-65 labeled NCp7. Purified HIV-1 NCp7 can be reconstituted with radioactive zinc-65 with a determined specific activity. By monitoring the release of radioactive zinc-65 caused by the reaction of a test compound with a retroviral NC protein, it is possible to determine the reactivity of the test compound.</p><p id="p0118" num="0118">A test compound can be added to a solution containing the NC protein complexed with radioactive zinc-65. Following the reaction, protein (reacted and unreacted) can be precipitated, for example, by immunoprecipitation or immunoadsorption methods using known antibodies, or by the addition of a calibrated amount of nucleic acid such that the NC protein saturates the binding sites on the nucleic acid matrix. Under conditions of low ionic strength, the saturated protein-nucleic acid complex forms a precipitate that can be removed by centrifugation. Alternatively, labeled nucleocapsid protein may be attached to a solid support, and test reagents added directly to the attached protein. Any reactions releasing zinc from the protein can be detected by the release of radioactive zinc-65 into the soluble supernatant. This general procedure can be automated depending on the equipment available. The invention may provide a kit supplying retroviral nucleocapsid protein and appropriate precipitating agents for detecting the ability of test compounds to remove zinc from the protein.</p><heading id="h0023"><b>3. Release Of Radioactive Zinc From Zinc-65 Labeled Whole Virus</b></heading><p id="p0119" num="0119">Another exemplary screening method of the invention measures release of radioactive zinc from zinc-65 labeled whole virus. Zinc is present in virus in quantities nearly stoichiometric with CCHC zinc finger arrays (<nplcit id="ncit0064" npl-type="s"><text>Bess (1992) J. Virol. 66: 840</text></nplcit>). Nearly all of the zinc is coordinated in the CCHC arrays (<nplcit id="ncit0065" npl-type="s"><text>Summers (1992) Protein Science 1: 563</text></nplcit>). Therefore, zinc released from a virus derives from zinc previously coordinated in CCHC arrays, rather than from unrelated proteins or other non-specific associations with the virion.</p><p id="p0120" num="0120">Purified virus can be produced from cells cultured in the presence of added zinc-65. Labeled virus can be isolated and purified by density gradient centrifugation in the presence of added EDTA to remove any unbound zinc. The purified virus can be any retrovirus of interest including, but not limited to, HIV-1, HIV-2 or SIV.</p><p id="p0121" num="0121">Compounds to be tested (compounds of the present invention) can be added to the purified radioactive virus under conditions appropriate for the test compound of choice (<nplcit id="ncit0066" npl-type="s"><text>Rice<!-- EPO <DP n="33"> --> (1993) Nature 361:473-475</text></nplcit>). Following the reaction, removal and/or inactivation of the reagent, the virus is disrupted by the addition of a non-ionic detergent (e.g., Triton X-100), and the viral core containing the NC protein complexed to nucleic acid is removed by centrifugation. Radioactive zinc-65 released into the supernatant indicates that the test compound penetrated the intact virus and disrupted the NC protein-zinc complex. The invention provides kits to determine whether test compounds can remove retroviral NC-chelated zinc; they can contain, inter alia, intact retrovirus particles with radioactive zinc-65 incorporated into their NC proteins, appropriate reaction buffers and a non-ionic detergent.</p><heading id="h0024"><b>4. Fluorescence-Based Detection of Zinc Dissociation from Protein</b></heading><p id="p0122" num="0122">Another exemplary screening method of the invention is a fluorescence-based detection of zinc dissociation from protein. This method measures changes in the intrinsic fluorescence of aromatic protein moieties. It is commonly used to monitor a reaction which involves a change in protein conformation. In the present invention, fluorescence can be used to monitor the loss of metal ion from a zinc finger, e.g., the loss of zinc from a CCHC retroviral zinc finger protein, after contact with a compound of the present invention. The intrinsic fluorescence of Trp 37 in the second zinc finger of HIV-1 NC protein can be used to monitor nucleic acid binding and conformation of the zinc finger complex.</p><p id="p0123" num="0123">Zinc ejection is measured by the ability of compounds to chemically attack the cysteines in purified NCp7 protein resulting in a loss of fluorescence due to the movement of the tryptophan 37 residue from an exposed to an internal position on the protein. Zinc ejection can be measured and expressed as either percent decrease in total fluorescence or decrease in relative fluorescence units per min during a 30 min assay (RFU/min). A compound is considered within the scope of the invention if any amount of zinc ejection is detected.</p><p id="p0124" num="0124">Artificial fluorescent probes can also be incorporated into a protein to provide for the detection of changes in conformation. Poly ethino-adenine, e.g., can be used as a fluorescent nucleotide to measure the extent of interaction between a compound of the present invention and a zinc finger (see, <nplcit id="ncit0067" npl-type="s"><text>Karpel (1987) J. Biol. Chem 262:4961</text></nplcit>). Finally, a variety of known fluorescent zinc chelators capable of complexing liberated zinc may be used to monitor zinc loss. By monitoring the release of zinc from the CCHC zinc finger arrays, the effect of a given reagent may be determined (<nplcit id="ncit0068" npl-type="s"><text>Rice (1996) J. Med. Chem. 39:3606-3616</text></nplcit>;<nplcit id="ncit0069" npl-type="s"><text> Rice (1996) Science 270:1194-1197</text></nplcit>).<!-- EPO <DP n="34"> --></p><heading id="h0025"><b>5. Detection Of Disulfide Cross-Linked NC Protein By Gel-Mobility Shift Assays</b></heading><p id="p0125" num="0125">Another exemplary screening method of the invention involves detection of disulfide cross-linked NC protein by Gel-Mobility Shift Assays. Purified concentrated retrovirus and antisera against the purified NC protein of the virus can be used to test the ability of a specific compound to penetrate the virus and react with the NC protein by forming disulfide complexes in the core of the virus. Compounds are mixed with the whole retrovirus under reaction conditions appropriate for each compound. The virus is then removed from the reagent by centrifugation and disrupted in, e.g., standard SDS-PAGE sample buffer with (reduced) and without (non-reduced) 2-mercaptoethanol. The viral proteins are then separated by standard SDS--PAGE and the sample examined for the presence or absence of the monomeric zinc finger protein in the non-reduced sample. Depending upon the virus used in the experiment and the conditions of electrophoresis, the zinc finger protein can be visualized by protein staining methods, or by immuno-blot methods. Compounds which react with the zinc finger protein by attacking the zinc finger complexes and forming disulfide cross-linked products inactivate the virus. Thus, compounds of interest (<i>i.e</i>., those which cause cross-linking), including the compounds of the present invention, reduce the amount of monomeric zinc finger protein detected.</p><p id="p0126" num="0126">The treated virions can also be tested for infectivity. The virions are suspended in media (rather than solubilized) and added to target cells. The cultures are then examined to determine whether the virions are still active. To determine whether the treated virus particles are active, the cells are monitored for the presence of intracellularly-synthesized viral RNA using, for example, the polymerase chain reaction (PCR) (<nplcit id="ncit0070" npl-type="s"><text>Rice (1993) Proc. Natl. Acad. Sci. USA 90: 9721</text></nplcit>;<nplcit id="ncit0071" npl-type="s"><text> Turpin (1996) J. Virol. 70: 6180</text></nplcit>). Alternatively, cytoprotection assays can be used (<nplcit id="ncit0072" npl-type="s"><text>Weislow (1993) J. Natl. Cancer Inst. 81: 577</text></nplcit>). An example of a compound which can be used as a control in the gel mobility shift assay is azodicarbonamide (ADA), a compound which is commercially available from the Aldrich Chemical Company (Milwaukee, WI). ADA also inactivates HIV-1 virus, as determined using the PCR assay described above.</p><p id="p0127" num="0127">The invention may provide a kit incorporating the gel-mobility shift concept to screen the compounds of the present invention for various activities. For example, it can be used to identify and study compounds which are able to penetrate intact virus and to induce disulfide cross-links in the viral zinc finger proteins. An exemplary kit would contain, for example,<!-- EPO <DP n="35"> --> purified concentrated retrovirus and appropriate size standards to monitor the change in mobility through the gel due to disulfide cross-linking.</p><heading id="h0026"><b>6. High Performance Liquid Chromatography of Purified NC Proteins For Structural Characterization of Reaction Products</b></heading><p id="p0128" num="0128">Another exemplary screening method of the invention uses high performance liquid chromatography (HPLC) of purified NC proteins for structural characterization of proteins reacted with the compounds of the present invention. For example, highly purified retroviral zinc finger proteins can be produced by expression from vectors generated through recombinant DNA technology. These proteins, when reconstituted with zinc, as described by <nplcit id="ncit0073" npl-type="s"><text>Summers (1992) Protein Science 1: 563-567</text></nplcit>, provide the source of the NC proteins containing the zinc fingers that are the targets for attack by compounds of the present invention. When the zinc finger proteins react with identified compounds, the reaction produces a covalent change in the zinc finger protein, and the modified protein can be separated from the unreacted protein by, for example, reversed phase HPLC.</p><p id="p0129" num="0129">The purified proteins and these separation methods are used to obtain sufficient modified protein (<i>i.e.,</i> products of the reaction) for chemical and structural analysis. The purified reaction products are isolated and their structures determined by standard N-terminal Edman degradation. However, for any specific reagent, the gradients and HPLC conditions will depend upon the NC protein and the reaction products. This procedure can be used to identify compounds which react with HIV-1 zinc fingers. The invention may provide kits standardizing these techniques; they may contain, for example, purified retroviral zinc finger proteins.</p><heading id="h0027"><b>7. Nuclear Magnetic Resonance (NMR) -Based Detection of Zinc Loss</b></heading><p id="p0130" num="0130">Another exemplary screening method of the invention uses NMR to monitor the loss of zinc from a protein upon contact with a compound of the present invention, <i>e.g.,</i> a retroviral zinc finger protein (see, <i>e.g.,</i> <nplcit id="ncit0074" npl-type="s"><text>Rice (1993) Nature 361: 473-475</text></nplcit>; <nplcit id="ncit0075" npl-type="s"><text>McDonnell (1997) J. Med. Chem. 40: 1969</text></nplcit>; <nplcit id="ncit0076" npl-type="s"><text>Rice (1997) Nature Medicine 3: 341-345</text></nplcit>). One of skill is familiar with the general technique of NMR and its many applications to monitor protein-ligand interactions. Briefly, the atoms in retroviral zinc finger proteins bound to zinc share a different local environment than zinc finger proteins that lack zinc. The difference in local environment leads to distinct NMR spectra for protein molecules that bind zinc, versus those that do not. By monitoring, for example, the proton (1H) spectrum of a sample containing<!-- EPO <DP n="36"> --> metal ion-chelated zinc finger protein and a compound of the present invention over time, it is possible to measure whether the compound causes the protein to loose its zinc ion. Since NMR can be used to provide the percent of protein molecules that are bound to zinc over time, it is also possible to use this technique to define the reaction kinetics of a given reaction. Similarly, NMR may be used to monitor the effect of test compounds upon the binding of zinc finger proteins to nucleic acid complexes. The invention may provide kits containing e.g., purified retroviral zinc finger proteins and oligonucleotides, in addition to the compounds of the present invention, to standardize the practice of this method.</p><heading id="h0028"><b>V. General Methods</b></heading><heading id="h0029"><b>A. Detection of Antiviral Activity</b></heading><p id="p0131" num="0131">Certain compounds within the scope of the present invention have displayed antiviral activity (<i>i.e</i>., any ability to decrease or diminish the transmission of or the replicative capacity of a virus). The antiviral activity of these compounds can be determined empirically by clinical observation or objectively using any in vivo or ill vitro test or assay, e. g., the XTT cytoprotection assay (described herein), measuring Tat-induced activity (as in the HeLa-CD4-LTR-beta-gal (MAGI cells) assay and detecting Tat-induced beta-galactosidase activity, see, <i>e.g.,</i> <nplcit id="ncit0077" npl-type="s"><text>Tolcunaga (1998) J. Virol. 72: 6257-6259</text></nplcit>), and the like.</p><p id="p0132" num="0132">One exemplary means to determine antiviral activity is with CEM-SS cells and virus (<i>e.g.,</i> HIV-1RF) (MOI = 0.01) using the XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-5-[ (phenylamino)carbonyl]-2H-tetrazolium hydroxide) cytoprotection assay, as described by <nplcit id="ncit0078" npl-type="s"><text>Rice (1993) PNAS 90: 9721-9724</text></nplcit>, and <nplcit id="ncit0079" npl-type="s"><text>Rice (1997) Antimicrob. Agents Chemother. 41: 419-426</text></nplcit>. Briefly, cells are infected with HIV-1RF (or other virus to be tested) in the presence of various dilutions of test compounds or control compounds. The cultures are incubated for seven days. During this time, control cultures without protective compounds (<i>i.e.,</i> compounds with anti-viral activity) replicate virus, induce syncytia, and result in about 90% cell death. The cell death is measured by XTT dye reduction. XTT is a soluble tetrazolium dye that measures mitochondrial energy output, similar to MTT. Positive controls using dextran sulfate (an attachment inhibitor) or 3'-azido-2', 3'-dideoxythymidine, AZT (a reverse transcriptase inhibitor) are added to each assay. Individual assays are done in duplicate using a sister plate method. Effective antiviral concentrations providing 50% cytoprotection (ECso), and cellular growth inhibitory concentrations causing 50% cytotoxicity<!-- EPO <DP n="37"> --> (IC<sub>50</sub>) are calculated. Activity data using this assay for selected compounds of the present invention are presented in Table 1 below.</p><p id="p0133" num="0133">Alternatively, any virus can be grown in culture, or in an <i>in vivo</i> (animal) model, in the presence or absence of a compound or a compound-containing pharmaceutical formulation to test for anti-viral, viral transmission-inhibiting activity and efficacy. Any virus, assay or animal model which would be apparent to one of skill upon review of this disclosure can be used, see, e.g., <nplcit id="ncit0080" npl-type="s"><text>Lu (1997) Crit. Rev. Oncog. 8:273-291</text></nplcit>; <nplcit id="ncit0081" npl-type="s"><text>Neildez (1998) Virology 243:12-20</text></nplcit>; <nplcit id="ncit0082" npl-type="s"><text>Geretti (1998) J. Gen. Virol. 79:415-421</text></nplcit>; <nplcit id="ncit0083" npl-type="s"><text>Mohri (1998) Science 279:1223-1227</text></nplcit>; <nplcit id="ncit0084" npl-type="s"><text>Lee (1998) Proc. Natl. Acad. Sci. USA 95:939-944</text></nplcit>; <nplcit id="ncit0085" npl-type="s"><text>Schwiebert (1998) AIDS Res. Hum. Retroviruses 14:269-274</text></nplcit>.</p><p id="p0134" num="0134">For in vitro assays, any measurable decrease in the viral load of a culture grown in the presence of a compound test compound as compared to a positive or negative control compound is indicative of an anti-viral, transmission-inhibiting effect. Generally, between 10% and 99% reduction in viral load is observed, but typically a reduction of at least 30% is considered significant. Any relevant criteria can be used to evaluate the antiviral efficacy of a compound of the present invention or its composition or formulation.</p><heading id="h0030"><b>B. Cloning and Expression of Retroviral Nucleocapsid Proteins</b></heading><p id="p0135" num="0135">Certain compounds of the present invention are capable of dissociating a metal ion from a zinc finger <i>in vitro.</i> Zinc finger containing proteins are used to detect the dissociation of a metal ion from a zinc finger motif and in the methods and kits of the present invention. General laboratory procedures for the cloning and expression of zinc finger motifs and proteins containing these motifs can be found, <i>e.g.,</i> current editions of <nplcit id="ncit0086" npl-type="b"><text>Sambrook, et al., Molecular Cloning A Laboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989</text></nplcit>; <nplcit id="ncit0087" npl-type="b"><text>CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed. Greene Publishing and Wiley-Interscience, New York (1987</text></nplcit>). Sequences and sources of zinc fingers, including nucleic acids, proteins and viral sources, are publicly available, for example, through electronic databases, such as, <i>e.g.,</i> The National Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/Entrez/, or, The National Library of Medicine at http://www.ncbi.nhn.nih.gov/PubMed/.</p><p id="p0136" num="0136">The nucleic acid compositions that may be used to express zinc finger-containing proteins, whether RNA, cDNA, genomic DNA, or a hybrid of the various combinations, can be isolated from natural sources, or may be synthesized <i>in vitro.</i> Recombinant DNA techniques can be used to produce polypeptides. In general, the DNA encoding the<!-- EPO <DP n="38"> --> polypeptide or peptide of interest are first cloned or isolated in a form suitable for ligation into an expression vector. After ligation, the vectors containing the DNA fragments or inserts are introduced into a suitable host cell for expression of the recombinant polypeptides. The polypeptides are then isolated from the host cells. The nucleic acids may be present in transformed or transfected whole cells, in a transformed or transfected cell lysate, or in a partially purified or substantially pure form. Techniques for nucleic acid manipulation of genes encoding zinc finger-containing proteins, such as subcloning nucleic acid sequences into expression vectors, labeling probes, DNA hybridization, and the like are described, e. g., in Sambrook and Ausubel, supra.</p><p id="p0137" num="0137">Once the DNAs are isolated and cloned, one can express the desired polypeptides in a recombinantly engineered cell such as bacteria, yeast, insect, or mammalian cells. One of skill in the art is knowledgeable in the numerous expression systems available for expression of the recombinantly produced proteins.</p><heading id="h0031"><b>C. Evaluating activity in vivo</b></heading><p id="p0138" num="0138">Compounds of the present invention are often highly active against simian immunodeficiency virus (SIV). Such compounds can be utilized for the treatment of SIV infections in, for example, macaque monkeys. This activity provides an ideal model for use in the optimization of formulations and administration regimens.</p><p id="p0139" num="0139">Alternatively, any virus can be grown in culture, or in an in vivo (animal) model, in the presence or absence of a compound of the present invention or a formulation containing such compound to test for antiviral, viral transmission-inhibiting activity and efficacy. Any virus, assay or animal model, which would be apparent to one of skill upon review of this disclosure, can be used, see, e. g. , <nplcit id="ncit0088" npl-type="s"><text>Lu (1997) Crit. Rev. Oncol. 8: 273-291</text></nplcit>; <nplcit id="ncit0089" npl-type="s"><text>Neildez (1998) Virology 243: 12-20</text></nplcit>; <nplcit id="ncit0090" npl-type="s"><text>Geretti (1998) J. Gen Virol 79: 415-421</text></nplcit>; <nplcit id="ncit0091" npl-type="s"><text>Mohri (1998) Science 279: 1223-1227</text></nplcit>; <nplcit id="ncit0092" npl-type="s"><text>Lee (1998) Proc. Natl. Acad. Sci. USA 95: 939-944</text></nplcit>;<nplcit id="ncit0093" npl-type="s"><text> Schwiebert (1998) AIDS Res &amp; Hum. Retroviruses 14: 269-274</text></nplcit>.</p><heading id="h0032"><b>VI. EXAMPLES</b></heading><p id="p0140" num="0140">The following examples describe ways to practice the present invention. They are in no way intended to limit the scope of the present invention.<!-- EPO <DP n="39"> --></p><heading id="h0033"><b>A. Synthesis of compounds</b></heading><p id="p0141" num="0141">Compounds of the present invention, including intermediates used in the making of these compositions, such as disulfides, can be synthesized by any method known in the art, see, <i>e.g.,</i> <nplcit id="ncit0094" npl-type="b"><text>Beilstein Handbook of Organic Chemistry, supra; Gilman, et al, supra</text></nplcit>. The following are exemplary synthetic protocols:</p><heading id="h0034"><b>1. Example 1: Synthesis of 2,2'-dithiobis(5-chlorobenzoic acid)</b></heading><p id="p0142" num="0142">A freshly made solution of sodium disulfide (Na<sub>2</sub>S<sub>2</sub>) was prepared as follows: A mixture of sodium sulfide (Na<sub>2</sub>S.9H<sub>2</sub>O) (15.40 g, 64.1 mmol) and powdered sulfur (2.06 g, 64.1 mmol) in 50 ml water was heated and efficiently stirred to dissolve the sulfur. A solution of sodium hydroxide (2.33 g, 58.3 mmol) in 30 ml water was then added to the hot solution, and the mixture was cooled to 0 ¬∞C.</p><p id="p0143" num="0143">To a solution of 2-amino-5-chlorobenzoic acid (10 g, 58.3 mmol) in 50 ml water was added 6 M hydrochloric acid (23.3 ml, 139.9 mmol). The mixture was cooled to 0 ¬∞C., and a chilled solution of 2.0 M sodium nitrite (29.1 ml, 58.2 mmol) was added gradually while maintaining the temperature below 5 ¬∞C.</p><p id="p0144" num="0144">To the alkaline solution of sodium disulfide was added the above diazotized solution with constant stirring, at a temperature below 5 ¬∞C. The mixture was allowed to warm to room temp. and was stirred overnight. The solution was acidified with 6 M hydrochloric acid (21 ml, 126 mmol) until the pH was less than 2. The precipitate thus obtained was filtered and washed with water.</p><p id="p0145" num="0145">In order to remove excess sulfur, the precipitate was dissolved by boiling with a solution of anhydrous sodium carbonate Na<sub>2</sub>CO<sub>3</sub> (3.52 g, 33.2 mmol) in 30 ml water (pH ‚àº8.1). The undissolved material was filtered off and washed with hot water. The filtrate and washes were acidified in order to reprecipitate the product. The product was filtered off and crystallized from ethanol. Yield: 9.0 g (82.3%). TLC (EM silica on glass) showed one spot (UV), using chloroform-ethyl acetate 7:3 v/v as the mobile phase. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 7.26(d, 2H, Ar-H), 7.34(d, 2H, Ar-H), 7.98(s, 2H, Ar-H), 13.96(brs, 2H, COOH).</p><heading id="h0035"><b>2. Example 2: Synthesis of 3,3'-dithiobis(benzoic acid)</b></heading><p id="p0146" num="0146">This disulfide was prepared from 3-aminobenzoic acid using the same procedure as described above.<br/>
<sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 7.24-7.32(m, 2H, Ar-H), 7.36(d, 2H, Ar-H), 7.44(d, 2H, Ar-H), 8.04(s, 2H, Ar-H), 13.08(brs, 2H, COOH).<!-- EPO <DP n="40"> --></p><heading id="h0036"><b>3. Example 3: Synthesis of 2,2'-dithiobis(nicotinoyl chloride)</b></heading><p id="p0147" num="0147">A mixture of 2-mercaptonicotinic acid (1.0 g, 6.45 mmol), toluene (10 ml) and thionyl chloride (5 ml) was refluxed for 3 h. The yellow product, which crystallized out on cooling, was collected and washed with carbon disulfide and then with chloroform; mp, 212-214¬∞C, yield 85%. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 7.26-7.32(m, 2H, H-5 &amp;H-5'), 8.26(d, 2H, H-6&amp;H-6'), 8.52(d, 2H, H-4&amp;H-4').</p><heading id="h0037"><b>4. Example 4: Synthesis of Di-N-succinimidyl 2,2'-dithiobis(benzoate)</b></heading><p id="p0148" num="0148">To a solution of 2,2'-dithiosalicylic acid (2.0 mmol) in a mixture of THF (14 ml) and 2-propanol (6 ml) was added <i>N</i>-hydroxysuccinimide (4.4 mmol) and 1,3-diisopropylcarbodiimide (4.1 mmol). The solution was stirred at room temp. for 4 h. The white precipitate (product) thus obtained was filtered and washed with 2-propanol (20 ml) in portions, yielding di-<i>N</i>-succiniinidyl 2,2'-dithiobis(benzoate) (89%). <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 3.0(s, 8H, 4CH<sub>2</sub>), 7.52-7.64(m, 2H, Ar-H), 7.80-7.94(m, 4H, Ar-H), 8.32(d, 2H, Ar-H).</p><heading id="h0038"><b>5. Example 5: Synthesis of Di-N-succinimidyl 3,3'-dithiobis(benzoate)</b></heading><p id="p0149" num="0149">This compound was prepared from 3,3'-dithiobis(benzoic acid) in the same manner as the above, 2,2' isomer. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 2.90(s, 8H, 4CH<sub>2</sub>), 7.70(t, 2H, Ar-H), 7.96-8.06(m, 4H, Ar-H), 8.22(s, 2H, Ar-H).</p><heading id="h0039"><b>6. Example 6: Synthesis of Di-N-succinimidyl 2,2'-dithiobis(5-chlorobenzoate)</b></heading><p id="p0150" num="0150">This compound was prepared from 2,2'-dithiobis(5-chlorobenzoic acid) in the same manner as for the above derivatives. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 2.92(s, 8H, 4CH<sub>2</sub>), 7.74(d, 2H, Ar-H), 7.86(d, 2H, Ar-H), 8.24(s, 2H, Ar-H).</p><heading id="h0040"><b>7. Example 7: Synthesis of Di-N-succinimidyl 2,2'-dithiobis(nicotinoate)</b></heading><p id="p0151" num="0151">A mixture of crude 2,2'-dithiobis(nicotinoyl chloride) (0.35 g, 1.0 mmol), <i>N-</i>hydroxysuccinimide (0.26 g, 2.2 mmol), diisopropylcarbodiimide (0.33 ml, 2.1 mmol, added to activate free carboxyl groups present in the crude bis-acid chloride), THF (9 ml) and 2-propanol (4 ml) was stirred overnight. The precipitated product was collected and washed<!-- EPO <DP n="41"> --> with 2-propanol (15 ml) and dried <i>in vacuo.</i> Yield: 80%. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 2.94(brs, 8H, 4CH<sub>2</sub>)7.47-7.52(m, 2H, H-5 &amp;H-5'), 8.58(d, 2H, H-6&amp;H-6'), 8.76(d, 2H, H-4&amp;H-4').</p><heading id="h0041"><b>8. Example 8: Synthesis of N-Benzyloxycarbonyl (Z)-Œ≤-alanine amide</b></heading><p id="p0152" num="0152">A well stirred solution of Z-Œ≤-alanine (11.72 g, 52.6 mmol) and N-methylmorpholine (5.88 ml, 52.5 mmol) in 300 ml CH<sub>2</sub>Cl<sub>2</sub> was cooled to -20 ¬∞C, and. isobutyl chloroformate (6.6 ml, 50.0 mmol) was added. After being stirred for 20 min, 2.0 M ammonia in 2-propanol (30 ml, 60 mmol) was added gradually at -20 ¬∞C with constant stirring. The pure product was isolated by extraction with dichloromethane/water. Yield, 6.0 g (55 %); melting point, 130-131 ¬∞C.</p><p id="p0153" num="0153">Z-D-Alanine amide was prepared in like manner as Œ≤-alanine amide.</p><heading id="h0042"><b>9. Example 9: Synthesis of N,N'-(2,2'-Dithiobisbenzoyl)bis(Œ≤-alaninamide)</b></heading><p id="p0154" num="0154">Z-Œ≤-alaninamide (5.11 g, 23 mmol) was dissolved in 100 ml methanol under nitrogen atmosphere, and 10% Pd/C (11% of the sample weight, 0.60 g) was suspended in 40 ml of methanol and added The mixture was hydrogenated at 1 atm for 3 h. TLC was used to check for complete removal of the Z group. The Pd/C was filtered off and the filtrate was rotary evaporated to give an oily residue(‚àº2.18g). The residue was diluted with 50 ml DMF, di-<i>N-</i>succinimidyl 2,2'-dithiobis(benzoate) (5.01 g, 10 mmol) was added, and the reaction mixture was stirred overnight. The DMF was rotary evaporated and 50 ml of water was added to the residue. The precipitate obtained was filtered and dried over CaCl<sub>2</sub>. Yield: 3.91 g (87%); <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) : 2.44(t, 4H, 2CH<sub>2</sub>), 3.46(q, 4H, 2CH<sub>2</sub>), 6.90(brs, 2H, NH<sub>2</sub>), 7.34(t, 2H, Ar-H), 7.40-7.56(m, 4H, Ar-H&amp;NH<sub>2</sub>), 7.66(d, 4H, Ar-H), 8.72(t, 2H, NH).</p><heading id="h0043"><b>10. Example 10: Synthesis of N,N'-(2,2'-Dithiobisnicotinoyl)bis(glycinamide)</b></heading><p id="p0155" num="0155">To a mixture of di-<i>N</i>-succinimidyl 2,2'-dithiobis(nicotinoate) (0.50 g, 1 mmol), glycinamide hydrochloride (0.33 g, 3, mmol) and triethylamine (0.4 ml, 3 mmol) in DMF (5 ml) was stirred for 8 hr. After completion of the reaction, the solvent was evaporated to dryness and diluted with water. The precipitate thus obtained was filtered and dried over CaCl<sub>2</sub>. Yield: 85%. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 3.85(d, 4H, 2CH<sub>2</sub>), 7.13(brs, 2H, 2NH<sub>2</sub>), 7.26-7.30(m, 2H, H-5 &amp;H-5'), 7.47(brs, 2H, 2NH<sub>2</sub>), 8.12(d, 2H, H-6&amp;H-6'), 8.48(d, 2H, H-4&amp;H-4'), 8.99(t, 2H, 2NH).<!-- EPO <DP n="42"> --></p><heading id="h0044"><b>11. Example 11: Synthesis of N-(2-Mercaptobenzoyl)-Œ≤-alaninamide</b></heading><p id="p0156" num="0156">To the mixture of <i>N,N'</i>-(2,2'-dithiobisbenzoyl)bis(Œ≤-alaninamide) (2.00 g, 4.5 mmol) in DMF (18 ml) and water (2 ml) was added tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (1.5g, 5.2 mmol) and triethylamine (0.50 ml, 4.6 mmol). The mixture was stirred at room temp. for 1 h and then added to ethyl ether (200 ml). The precipitate was collected, washed with water (3x20 ml) and dried under vacuum to yield 1.56 g (77%) of the title compound. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 2.40(t, 2H, CH<sub>2</sub>), 3.42(q, 2H, CH<sub>2</sub>), 5.40(s,1H, SH), 6.90(s,1H, NH<sub>2</sub>), 7.20(t,1H, Ar-H), 7.33(t, 1H, Ar-H), 7.40-7.55(m, 3H, Ar-H&amp;NH<sub>2</sub>), 8.48(t, 1H, NH).</p><heading id="h0045"><b>12. Example 12: Synthesis of N-(1,2-dihydro-2-thioxonicotinoyl)glycinamide</b></heading><p id="p0157" num="0157">To a stirred suspension of <i>N,N'</i>-(2,2'-dithiobisnicotinoyl)bis(glycinamide) (0.42 g, 1.0 mmol) in 1.0 M HCl (5 ml) was added slowly sodium metabisulfite (0.5g, 5 mmol), dissolved in about 1 ml of water. The mixture was stirred at room temp. for 1 h, and the solid material was collected by filtration and dried over CaCl<sub>2</sub>. Yield: 90%. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>): 3.91(d, 2H, CH<sub>2</sub>), 7.0(t, 1H, H-5), 7.14(brs, 1H, NH<sub>2</sub>), 7.50(brs, 1H, NH<sub>2</sub>), 7.94(t, 1H, H-6), 8.37(d, 1H, H-4), 10.65(t, 1H, NH), 14.10 (brs, 1H, NH).</p><heading id="h0046"><b>13. Example 13: Synthesis of N-[2-(tert-Butylcarbamylthio)benzoyl]-Œ≤-alaninamide</b></heading><p id="p0158" num="0158">To a well stirred mixture of <i>N</i>-(2-mercaptobenzoyl)-Œ≤-alaninaniide (0.45 g, 2.0 mmol) in 8 ml DMF was added <i>tert</i>-butyl isocyanate (3.0 mmol). The reaction mixture was stirred for 8-10 h at room temp. After completion of the reaction, all of the DMF was removed <i>in vacuo</i> and the residue was treated with ethyl ether. The white precipitate that formed was washed with water, dried <i>in vacuo</i>/CaCl<sub>2</sub> and crystallized from acetonitrile. Yield: 89%. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 1.30(s, 9H, 3CH<sub>3</sub>), 2.38(t, 2H, CH<sub>2</sub>), 3.40(q, 2H, CH<sub>2</sub>), 6.86(brs, 1H, NH<sub>2</sub>), 7.30-7.60(m, 5H, Ar-H, NH<sub>2</sub>), 8.06(s, 1H, NH), 8.26(t, 1H, NH).</p><heading id="h0047"><b>14. Example 14: Synthesis of N-[2-(2-Bromoethylcarbamylthio)benzoyl]-Œ≤-alaninamide</b></heading><p id="p0159" num="0159">To a solution of <i>N</i>-(2-mercaptobenzoyl)-Œ≤-alaninamide (0.90 g, 4.0 mmol) in DMF (20 ml) was added 2-bromoethyl isocyanate (0.91 g, 6.0 mmol). The reaction mixture was stirred for 6 h. The solvent was evaporated to dryness, and the residue was treated with ethyl<!-- EPO <DP n="43"> --> ether (20 ml) with vigorous stirring. The precipitate obtained was filtered, washed with water and dried over CaCl<sub>2</sub>. Yield: 87%. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 2.36(t, 2H, CH<sub>2</sub>), 3.42(q, 2H, CH<sub>2</sub>), 3.54(s,4H, 2CH<sub>2</sub>), 6.88(brs, 1H, NH<sub>2</sub>), 7.36-7.66(m, 5H, Ar-H, NH<sub>2</sub>), 8.26(t, 1H, NH), 8.66(brs, 1H, NH).</p><heading id="h0048"><b>15. Example 15: Synthesis of N-[2-(2-Pyridinioethylcarbamylthio)benzoyl]-Œ≤-alaninamide bromide</b></heading><p id="p0160" num="0160">A solution of <i>N</i>-[2-(2-bromoethylcarbamylthio)benzoyl]-Œ≤-alaninamide (0.37 g, 1.0 mmol) in pyridine (5 ml) was stirred for 8 h under nitrogen. The pyridine was removed <i>in vacuo,</i> and the crude product was purified by column chromatography on silica using chloroform-methanol(7:3 v/v) as eluent. Yield: 82%. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 2.38(t, 2H, CH<sub>2</sub>), 3.40(q, 2H, CH<sub>2</sub>), 3.72(q,2H, CH<sub>2</sub>), 4.72(t, 2H, CH<sub>2</sub>), 6.92(brs, 1H, NH<sub>2</sub>), 7.36-7.58(m, 5H, Ar-H, NH<sub>2</sub>), 8.26(t, 2H, Py-H), 8.36(t, 1H, NH), 8.52(t, 1H, NH), 8.66(t, 1H, Py-H), 9.12(d, 2H, Py-H).</p><heading id="h0049"><b>16. Example 16: Synthesis of N-[2-(2-Bromoethyloxycarbonylthio)benzoyl]glycinamide</b></heading><p id="p0161" num="0161">To a solution of <i>N</i>-(2-mercaptobenzoyl)glycinamide (1.05 g, 5.0 mmol) in <i>N,N-</i>dimethylacetamide (DMA, 25 ml) was added 2-bromoethyl chloroformate (1.22 g, 6.5 mmol). The reaction mixture was stirred for 8 h, the solvent was evaporated to dryness,. and the residue was triturated with ethyl ether (25 ml. The resulting precipitate was filtered, washed with water and dried over CaCl<sub>2.</sub> Yield: 89%. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 3.71(t, 1H, CH<sub>2</sub>), 3.78(d, 2H, CH<sub>2</sub>), 3.86(t, 1H, CH<sub>2</sub>), 4.45(t, 1H, CH<sub>2</sub>), 4.51(t, 1H, CH<sub>2</sub>), 7.11(brs, 1H, NH<sub>2</sub>), 7.30(brs, 1H, NH<sub>2</sub>), 7.36-7.58(m, 5H, Ar-H, NH<sub>2</sub>), 8.26(t, 2H, Py-H), 8.36(t, 1H, NH), 8.52(t, 1H, NH), 8.66(t, 1H, Py-H), 9.12(d, 2H, Py-H).</p><heading id="h0050"><b>17. Example 17: Synthesis of N-[2-(iso-Butyloxycarbonylthio)benzoyl]-L-alaninamide</b></heading><p id="p0162" num="0162">To a solution of <i>N</i>-(2-mercaptobenzoyl)-L-alaninamide (0.22 g, 1.00 mmol) in DMA (5 ml) was added <i>iso</i>-butyl chloroformate (0.2 g, 1.50 mmol), and the mixture was stirred for 8 h. The solvent was evaporated to dryness, and the residue was triturated with ethyl ether (25 ml). The precipitate obtained was filtered, washed with water and dried over CaCl<sub>2</sub>. Yield, 73%. The product was further purified by column chromatography on silica using chloroform-methanol (7:3 v/v) as eluent with 82% recovery. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) : 0.94(d,<!-- EPO <DP n="44"> --> 6H, 2CH<sub>3</sub>), 1.34(d, 3H, CH<sub>3</sub>), 1.96(m, 1H, CH), 4.06(d, 2H, CH<sub>2</sub>), 4.44(quintet, 1H, CH), 7.16(brs, 1H, NH<sub>2</sub>), 7.38(brs, 1H, NH<sub>2</sub>), 7.54-7. 80(m, 4H, Ar-H), 8. 42(d, 1H, NH).</p><heading id="h0051"><b>18. Example 18: Synthesis of N-[2-Methylthioimidothio) benzoyl]-alaninamide</b></heading><p id="p0163" num="0163">A mixture of N-(2-mercaptobenzoyl)-Œ≤-alaninamide (0.45 g, 2.00 mmol) and methyl thiocyanate (0.22 g, 3.00 mmol) in DMF (10 ml) was heated at 60¬∞C for 20 h. The solvent was removed <i>in vacuo</i> and the resulting residue was treated with ethyl ether. The precipitate obtained was collected, and pure product was isolated by column chromatography on silica using chloroform as eluent. Yield, 83%. <sup>1</sup>H NMR (DMSO-d6): 2.30-2.50(m, 5H, CH<sub>2</sub> &amp; CH<sub>3</sub>), 3.44(q, 2H, CH<sub>2</sub>), 6.90(brs, 1H, NH<sub>2</sub>), 7.36(t, 2H, Ar-H), 7.44(brs, 1H, NH<sub>2</sub>), 7.56-7.70(m, 2H, Ar-H), 8.02(d, 1H, NH), 8.60(t, 1H, NH).</p><heading id="h0052"><b>19. Example 19: Synthesis of N-[2- (Ethylthiocarbonylthio)benzoyl]-D-alaninamide</b></heading><p id="p0164" num="0164">To a solution of N-(2-mercaptobenzoyl)-D-alaninamide (0.22 g, 1.00 mmol) in DMF (5 ml) was added ethyl chlorothiolformate (0.19 g, 1.50 mmol) and the mixture was stirred for 8 h. The solvent was evaporated to dryness, and the resulting residue was treated with ethyl ether (25 ml) with vigorous stirring. The precipitate obtained was filtered, washed with water and dried over CaCl<sub>2</sub>, Yield, 73%. The product was further purified by column chromatography using chloroform-methanol (7:3 v/v) as eluent with 82% recovery. <sup>1</sup>H NMR (DMSO-d6) : 1.24(t, 3H, CH<sub>3</sub>), 1.34(d, 3H, CH<sub>3</sub>), 3.0(q, 2H, CH<sub>2</sub>), 4.40(quintet, 1H, CH), 7.14(brs, 1H, NH<sub>2</sub>), 7.36(brs, 1H, NH<sub>2</sub>), 7.50-7.76 (m, 4H, Ar-H), 8.4(d, 1H, NH).</p><heading id="h0053"><b>B. Antiviral Activity of Compounds of the Invention</b></heading><p id="p0165" num="0165">The invention may provide methods for inactivating viruses, and, compositions comprising inactivated viruses, including, <i>e.g.,</i> vaccine pharmaceutical compositions. The compounds of the present invention were demonstrated to have viral inactivating activity in mechanistic and target-based assays.</p><p id="p0166" num="0166">For <i>in vitro</i> assays, any measurable decrease in the viral load of a culture grown in the presence of a test compound as compared to a positive or negative control compound is indicative of an antiviral, transmission-inhibiting effect. Typically, at least a 30% reduction in viral load is observed, generally, between 10% and 99%. As discussed in the above definition section, any relevant criteria can be used to evaluate the antiviral efficacy of a composition or formulation containing a compound of the present invention.<!-- EPO <DP n="45"> --></p><heading id="h0054"><b>1. Example 20: XTT Assay</b></heading><p id="p0167" num="0167">A compound is within the scope of the invention if it displays any antiviral activity (i.e., any ability to decrease or diminish the transmission of or the replicative capacity of a virus). The antiviral activity can be determined empirically by clinical observation or objectively using any <i>in vivo</i> or <i>in vitro</i> test or assay, e.g., the XTT cytoprotection assay (described herein), measuring Tat-induced activity (as in the HeLa-CD4-LTR-beta-gal (MAGI cells) assay and detecting Tat-induced <i>beta</i>-galactosidase activity, see, <i>e.g.,</i> <nplcit id="ncit0095" npl-type="s"><text>Tokunaga (1998) J. Virol. 72: 6257-6259</text></nplcit>, and the like. A compound with any degree of measurable antiviral activity is within the scope of the invention even if no metal ion dissociation occurs or no metal ion dissociation is detectable.</p><p id="p0168" num="0168">One exemplary means to determine antiviral activity is with CEM-SS cells and virus (e.g., HIV-1RF) (MOI = 0.01) using the XTT {2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide} cytoprotection assay, as described by <nplcit id="ncit0096" npl-type="s"><text>Rice (1993) Proc. Natl. Acad. Sci. USA 90: 9721-9724</text></nplcit>, and <nplcit id="ncit0097" npl-type="s"><text>Rice (1997) Antimicrob. Agents &amp; Chemother. 41: 419-426</text></nplcit>. Briefly, cells are infected with HIV-1RF (or other virus to be tested) in the presence of various dilutions of test compounds and controls. The cultures are incubated for seven days. During this time, control cultures without protective compounds (<i>i.e.,</i> compounds with antiviral activity) replicate virus, induce syncytia, and result in about 90% cell death. The cell death is measured by XTT dye reduction. XTT is a soluble tetrazolium dye that measures mitochondrial energy output, similar to MTT. Positive controls using dextran sulfate (an attachment inhibitor) or 3'-azido-2,3-dideoxythymidine, AZT (a reverse transcriptase inhibitor), are added to each assay. Individual assays are done in duplicate using a sister plate method. Effective antiviral concentrations providing 50% cytoprotection (EC<sub>50</sub>), and cellular growth inhibitory concentrations causing 50% cytotoxicity (IC<sub>50</sub>) are calculated. Table 1 provides activity data for illustrative compounds of the present invention. Compound numbers therein refer to the numbers used in <figref idrefs="f0001">Figure 1</figref>.<!-- EPO <DP n="46"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title><b>Table 1 : ANTIVIRAL ACTIVITY USING XTT ASSAY</b></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="36mm"/><colspec colnum="2" colname="col2" colwidth="20mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="32mm"/><thead><row><entry align="center" valign="top"><b>Compound Number</b></entry><entry align="center" valign="top"><b>EC<sub>50</sub> (¬µM)</b></entry><entry align="center" valign="top"><b>IC<sub>50</sub> (¬µM)</b></entry><entry align="center" valign="top"><b>Therapeutic Index</b></entry></row></thead><tbody><row><entry align="center">9</entry><entry align="center">2.7</entry><entry align="center">790</entry><entry align="center">298</entry></row><row><entry align="center">10</entry><entry align="center">3.8</entry><entry align="center">&gt;200</entry><entry align="center">&gt;53</entry></row><row><entry align="center">11</entry><entry align="center">6.9</entry><entry align="center">165</entry><entry align="center">24</entry></row><row><entry align="center">12</entry><entry align="center">8.1</entry><entry align="center">102</entry><entry align="center">13</entry></row><row><entry align="center">13</entry><entry align="center">3.7</entry><entry align="center">42</entry><entry align="center">11</entry></row><row><entry align="center">14</entry><entry align="center">2.6</entry><entry align="center">666</entry><entry align="center">251</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="47"> --></p><heading id="h0055">4. <b>Example 23: Activity in other in vitro assays</b></heading><p id="p0169" num="0169">The compounds tested did not inhibit HIV-1 integrase, reverse transcriptase or protease enzyme activities. Assays for activity against HIV-1 reverse transcriptase rAdT (template/primer) and iCdG (template/primer) using recombinant HIV-1 reverse transcriptase were performed as described by <nplcit id="ncit0098" npl-type="s"><text>Rice (1997) Antimicrob. Agents &amp; Chemother. 41: 419-426</text></nplcit>. Substrate cleavage of recombinant HIV-1 protease in the presence of test compounds using an nuclear magnetic resonance-based methodology with the artificial substrate Ala-Ser-GluAsn-Trp-Pro-Ile-Val-amide (Multiple Peptide Systems, San Diego, CA) was performed as described by Rice (1997) supra. The ability of recombinant HIV-1 integrase to carry out 3' processing and strand transfer activities in the presence of test compounds was performed as described by <nplcit id="ncit0099" npl-type="s"><text>Buclcheit (1994) AIDS Res. &amp; Human Retroviruses 10: 1497-1506</text></nplcit>, and <nplcit id="ncit0100" npl-type="s"><text>Turpin (1998) Antimicrob. Agents &amp; Chemother. 42: 487-494</text></nplcit>.</p><heading id="h0056"><b>5. Example 24: Relative Rates of Hydrolysis</b></heading><p id="p0170" num="0170">One of the advantages of the compounds of the present invention over previously identified antiretroviral agents is their increased hydrolytic stability, which improves their biological activity and reduces the amount of compound that must be delivered to a treated subject to produce the desired effect. The following Table shows half-lives in minutes for selected compounds of the present invention in a hydrolysis assay, using the p24 inhibition<!-- EPO <DP n="48"> --> ELISA assay and the HIV transgenic mouse model spleen cells. A PATE compound having the following structure is included:
<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="63" he="67" img-content="chem" img-format="tif"/></chemistry>
<tables id="tabl0002" num="0002"><table frame="all"><title><b>Table 4. Relative rates of hydrolysis of compounds of the present invention.</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="35mm"/><colspec colnum="2" colname="col2" colwidth="21mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="33mm"/><colspec colnum="5" colname="col5" colwidth="50mm"/><thead><row><entry align="center" valign="top"><b>Compound Number</b></entry><entry align="center" valign="top"><b>EC<sub>50</sub> (¬µM)</b></entry><entry align="center" valign="top"><b>IC<sub>50</sub> (¬µM)</b></entry><entry align="center" valign="top"><b>Therapeutic Index</b></entry><entry align="center" valign="top"><b>Half-life for hydrolysis (in min.)</b></entry></row></thead><tbody><row><entry align="center">11</entry><entry align="char" char="." charoff="9">3.6</entry><entry align="center">&gt;250</entry><entry align="center">&gt;69</entry><entry align="center">244</entry></row><row><entry align="center">12</entry><entry align="char" char="." charoff="9">3.5</entry><entry align="center">136</entry><entry align="center">39</entry><entry align="center">465</entry></row><row><entry align="center">PATE</entry><entry align="char" char="." charoff="9">6.2</entry><entry align="center">&gt;316</entry><entry align="center">&gt;51</entry><entry align="center">165</entry></row></tbody></tgroup></table></tables></p><p id="p0171" num="0171">It is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reading the above description. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the appended claims.</p></description><claims mxw-id="PCLM56987612" lang="DE" load-source="patent-office"><!-- EPO <DP n="53"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verbindung und deren pharmazeutisch annehmbare Salze, wobei die Verbindung aus der Gruppe ausgew√§hlt wird, die besteht aus:
<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="133" he="48" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="139" he="45" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verbindung nach Anspruch 1, wobei es sich bei der Verbindung um
<chemistry id="chem0012" num="0012"><img id="ib0012" file="imgb0012.tif" wi="37" he="38" img-content="chem" img-format="tif"/></chemistry>
handelt.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Zusammensetzung, wobei die Zusammensetzung eine Verbindung nach Anspruch 1 umfasst.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Zusammensetzung nach Anspruch 3, die ferner einen Exzipienten umfasst, wobei der Exzipient wenigstens einen pharmazeutisch annehmbaren Tr√§ger oder Verd√ºnner umfasst.<!-- EPO <DP n="54"> --></claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Zusammensetzung nach Anspruch 3, ferner umfassend ein zweites antiretrovirales Mittel.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Zusammensetzung nach Anspruch 5, wobei das zweite antiretrovirale Mittel ein Mitglied ist, das aus der Gruppe gew√§hlt wird, die aus einem Nukleosid-Analog, einem Nukleotid-Analog, einem Reverse-Transkriptase-Inhibitor, einem Integrase-Inhibitor, einem Fusionsinhibitor und einem Protease-Inhibitor gebildet wird.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Zusammensetzung nach Anspruch 3, ferner umfassend Blutplasma, N√§hrmedien, Protein, eine pharmazeutische Zubereitung, eine kosmetische Zubereitung, eine Sperma- oder Oozytenzubereitung, Zellen, Zellkulturen, Bakterien, Viren, Nahrungsmittel oder Getr√§nke.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Anwendung einer Verbindung nach Anspruch 1 zur Abtrennung eines Metallions von einem zinkfingerhaltigen Protein, wobei die Anwendung das <i>in vitro</i> erfolgende Inkontaktbringen des zinkfingerhaltigen Proteins mit einer Verbindung nach Anspruch 1 umfasst.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Anwendung nach Anspruch 8, wobei das zinkfingerhaltige Protein ein virales Protein ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Anwendung nach Anspruch 9, wobei das virale Protein aus der Gruppe ausgew√§hlt wird, die aus einem Nukleokapsidprotein, einem Gag-Protein und einem Gag-Pol-Protein gebildet ist.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Anwendung nach Anspruch 10, wobei das Protein von einem Retrovirus abgeleitet ist, das aus der Gruppe ausgew√§hlt wird, die aus einem HIV-1-, einem HIV-2-, einem SIV-, einem BIV-, einem EIAV-, einem Visna-, einem CaEV-, einem HTLV-1-, einem BLV-, einem MPMV-, einem MMTV-, einem RSV-, einem MuLV-, einem FeLV-, einem BaEV- und einem SSV-Retrovirus gebildet wird.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Anwendung nach Anspruch 11, wobei das retrovirale Protein ein HIV-1-Protein ist.<!-- EPO <DP n="55"> --></claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Anwendung nach Anspruch 8, wobei das zinkfingerhaltige Protein von einem Virus abgeleitet ist, das aus der Gruppe ausgew√§hlt wird, die aus einer avi√§ren Sarkom-Retrovirusgruppe, einer S√§uger-B-Typ-Retrovirusgruppe, einer humanen T-Zell-Leuk√§mie-Retrovirusgruppe, einer bovinen Leuk√§mie-Retrovirusgruppe, einer D-Typ-Retrovirusgruppe, einer mit der murinen Leuk√§mie verwandten Gruppe und einer Lentivirusgruppe gebildet wird.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Anwendung nach Anspruch 13, wobei das zinkfingerhaltige Protein Teil eines intakten Virus ist.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Anwendung nach Anspruch 8, ferner umfassend den Nachweis der Abtrennung des Metallions vom Zinkfinger des zinkfingerhaltigen Proteins.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Anwendung nach Anspruch 15, wobei der Nachweis der Abtrennung des Metallions durchgef√ºhrt wird, indem ein Verfahren angewendet wird, das aus der Gruppe ausgew√§hlt wird, die aus Folgendem gebildet wird: Kapillarelektrophorese, Immunblotting, Kernspinresonanz (NMR), Hochleistungs-Fl√ºssigkeitschromatographie (HPLC), Nachweis der Freisetzung von radioaktivem Zink-65, Nachweis von Fluoreszenz und Nachweis einer Gelmobilit√§ts√§nderung.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Anwendung einer Zusammensetzung zur Inaktivierung eines Virus, wobei die Anwendung das <i>in vitro</i> erfolgende Inkontaktbringen eines Virus mit einer Zusammensetzung nach Anspruch 3 umfasst, wobei die Zusammensetzung eine Verbindung nach Anspruch 1 oder deren pharmazeutisch annehmbare Salze umfasst, wobei das Inkontaktbringen des Virus mit der Zusammensetzung das Virus inaktiviert.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Anwendung nach Anspruch 17, wobei das Retrovirus aus der Gruppe ausgew√§hlt wird, die aus einem HIV-1-, einem HIV-2-, einem SIV-, einem BIV-, einem EIAV-, einem Visna-, einem CaEV-, einem HTLV-1-, einem BLV-, einem MPMV-, einem MMTV-, einem RSV-, einem MuLV-, einem FeLV-, einem BaEV- und einem SSV-Retrovirus gebildet wird.<!-- EPO <DP n="56"> --></claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Anwendung nach Anspruch 18, wobei das Virus ein HIV-1-Retrovirus ist.</claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>Anwendung nach Anspruch 18, wobei das Virus aus der Gruppe ausgew√§hlt wird, die aus einem Retrovirus gebildet wird, das von einer avi√§ren Sarkom- und Leukose-Retrovirusgruppe, einer S√§uger-B-Typ-Retrovirusgruppe, einer humanen T-Zell-Leuk√§mie- und einer bovinen Leuk√§mie-Retrovirusgruppe, einer D-Typ-Retrovirusgruppe, einer mit der murinen Leuk√§mie verwandten Gruppe und einer Lentivirusgruppe abgeleitet wird.</claim-text></claim><claim id="c-de-01-0021" num="0021"><claim-text>Verwendung der Verbindung nach einem der Anspr√ºche 1 oder 2 zur Herstellung eines Medikaments zur Behandlung von Retrovirus-Erkrankungen.</claim-text></claim><claim id="c-de-01-0022" num="0022"><claim-text>Verwendung der Zusammensetzung nach einem der Anspr√ºche 3 bis 7 zur Herstellung eines Medikaments zur Behandlung von Retrovirus-Erkrankungen.</claim-text></claim><claim id="c-de-01-0023" num="0023"><claim-text>Verwendung der Verbindung nach einem der Anspr√ºche 1 oder 2 zur Herstellung eines topischen Mikrobizids zur Vorbeugung der √úbertragung von Retrovirus-Erkrankungen.</claim-text></claim><claim id="c-de-01-0024" num="0024"><claim-text>Verwendung der Zusammensetzung nach einem der Anspr√ºche 3 bis 7 zur Herstellung eines topischen Mikrobizids zur Vorbeugung der √úbertragung einer viralen Infektion bei Retrovirus-Erkrankungen.</claim-text></claim></claims><claims mxw-id="PCLM56987613" lang="EN" load-source="patent-office"><!-- EPO <DP n="49"> --><claim id="c-en-01-0001" num="0001"><claim-text>A compound and pharmaceutically acceptable salts thereof, wherein the compound is selected from the group consisting of:
<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="148" he="52" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="157" he="52" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The compound of claim 1, wherein said compound is:
<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="52" he="54" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="50"> --></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A composition, said composition comprising a compound according to claim 1.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The composition of claim 3 that comprises an excipient wherein said excipient in-cludes at least one pharmaceutically acceptable carrier or diluent.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The composition of claim 3, further comprising a second anti-retroviral agent.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The composition of claim 5, wherein said second anti-retroviral agent is a member selected from the group consisting of a nucleoside analogue, a nucleotide analogue, a reverse transcriptase inhibitor, an integrase inhibitor, a fusion inhibitor and a protease inhibitor.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The composition of claim 3, further comprising blood plasma, nutrient media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, bacteria, viruses, food or drink.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A use of a compound according to claim 1 for dissociating a metal ion from a zinc finger-containing protein, the use comprising contacting said zinc finger-containing protein <i>in vitro</i> with a compound according to claim 1.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The use of claim 8, wherein the zinc finger-containing protein is a viral protein.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The use of claim 9, wherein the viral protein is selected from the group consisting of a nucleocapsid protein, a Gag protein and a Gag-Pol protein.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The use of claim 10, wherein the protein is derived from a retrovirus selected from the group consisting of an HIV-1, an HIV-2, an SIV, a BIV, an EIAV, a Visna, a CaEV, an HTLV-1, a BLV, an MPMV, an MMTV, an RSV, an MuLV, a FeLV, a BaEV and an SSV retrovirus.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The use of claim 11, wherein the retroviral protein is an HIV-1 protein.<!-- EPO <DP n="51"> --></claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The use of claim 8, wherein the zinc finger-containing protein is derived from a virus selected from the group consisting of an avian sarcoma retroviral group, a mammalian B-type retroviral group, a human T cell leukemia retroviral group, a bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group and a lentivirus group.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The use of claim 13, wherein the zinc finger-containing protein is part of an intact virus.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The use of claim 8, further comprising detecting the dissociation of the metal ion from the zinc finger of the zinc finger-containing protein.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>The use of claim 15, wherein detecting the dissociation of the metal ion is carried out using a method selected from the group consisting of capillary electrophoresis, immunoblotting, nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), detecting release of radioactive zinc-65, detecting fluorescence and detecting gel mobility shift.</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>A use of a composition for inactivating a virus, the use comprising contacting a virus <i>in vitro</i> with a composition according to claim 3, the composition comprising a compound according to claim 1 or pharmaceutically acceptable salts thereof, wherein contacting the virus with said composition inactivates the virus.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>The use of claim 17, wherein the retrovirus is selected from the group consisting of an HIV-1, an HIV-2, an SIV, a BIV, an EIAV, a Visna, a CaEV, an HTLV-1, a BLV, an MPMV, an MMTV, an RSV, an MuLV, a FeLV, a BaEV and an SSV retrovirus.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>The use of claim 18, wherein the virus is an HIV-1 retrovirus.<!-- EPO <DP n="52"> --></claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>The use of claim 18, wherein the virus is selected from the group consisting of a retrovirus derived from an avian sarcoma and leukosis retroviral group, a mammalian B-type retroviral group, a human T cell leukemia and bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group and a lentivirus group.</claim-text></claim><claim id="c-en-01-0021" num="0021"><claim-text>Utilization of the compound according to any one of the claims 1 or 2 for the manufacturing of a medicament for the treatment of retroviral diseases.</claim-text></claim><claim id="c-en-01-0022" num="0022"><claim-text>Utilization of the composition according to any one of the claims 3 to 7 for the manufacturing of a medicament for the treatment of retroviral diseases.</claim-text></claim><claim id="c-en-01-0023" num="0023"><claim-text>Utilization of the compound according to any one of the claims 1 or 2 for the manufacturing of a topical microbicide to prevent the transmission of retroviral diseases.</claim-text></claim><claim id="c-en-01-0024" num="0024"><claim-text>Utilization of the composition according to any one of the claims 3 to 7 for the manufacturing of a topical microbicide to prevent the transmission of a viral infection in retroviral diseases.</claim-text></claim></claims><claims mxw-id="PCLM56987614" lang="FR" load-source="patent-office"><!-- EPO <DP n="57"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Compos√© et sels pharmaceutiquement acceptables de celui-ci, le compos√© √©tant choisi parmi le groupe compos√© de :
<chemistry id="chem0013" num="0013"><img id="ib0013" file="imgb0013.tif" wi="132" he="45" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0014" num="0014"><img id="ib0014" file="imgb0014.tif" wi="140" he="44" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Compos√© de la revendication 1, ledit compos√© √©tant :
<chemistry id="chem0015" num="0015"><img id="ib0015" file="imgb0015.tif" wi="42" he="43" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composition, ladite composition comprenant un compos√© selon la revendication 1.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composition de la revendication 3 comprenant un excipient, ledit excipient comprenant au moins un support ou diluant pharmaceutiquement acceptable.<!-- EPO <DP n="58"> --></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Composition de la revendication 3, comprenant en outre un deuxi√®me agent anti-r√©troviral.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Composition de la revendication 5, dans laquelle ledit deuxi√®me agent antir√©troviral est un membre choisi parmi le groupe compos√© d'un analogue nucl√©osidique, d'un analogue nucl√©otidique, d'un inhibiteur de la transcriptase inverse, d'un inhibiteur d'int√©grase, d'un inhibiteur de fusion et d'un inhibiteur de prot√©ase.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Composition de la revendication 3, comprenant en outre du plasma sanguin, fluides nutritifs, une prot√©ine, un produit pharmaceutique, un produit cosm√©tique, une pr√©paration de spermatozo√Ødes ou d'ovocytes, des cellules, des cultures cellulaires, des bact√©ries, des virus, des aliments ou des boissons.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Utilisation d'un compos√© selon la revendication 1 pour dissocier un ion m√©tallique d'une prot√©ine contenant un doigt de zinc, l'utilisation comprenant mettre en contact <i>in vitro</i> ladite prot√©ine contenant le doigt de zinc avec un compos√© selon la revendication 1.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Utilisation de la revendication 8, la prot√©ine contenant le doigt de zinc √©tant une prot√©ine virale.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Utilisation de la revendication 9, dans laquelle la prot√©ine virale est choisie parmi le groupe compos√© d'une prot√©ine nucl√©ocapside, d'une prot√©ine Gag et d'une prot√©ine Gag-Pol.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Utilisation de la revendication 10, dans laquelle la prot√©ine est d√©riv√©e d'un r√©trovirus choisi parmi le groupe compos√© d'un HIV-1, un HIV-2, un SIV, un BIV, un EIAV, un Visna, un CaEV, un HTLV-1, un BLV, un MPMV, un MMTV, un RSV, un MuLV, un FeLV, un BaEV et un SSV.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Utilisation de la revendication 11, dans laquelle la prot√©ine r√©trovirale est une prot√©ine HIV-1.<!-- EPO <DP n="59"> --></claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Utilisation de la revendication 8, dans laquelle la prot√©ine contenant le doigt de zinc est d√©riv√©e d'un virus choisi parmi le groupe compos√© d'un groupe de r√©trovirus du sarcome aviaire, d'un groupe de r√©trovirus de type B de mammif√®re, d'un groupe de r√©trovirus de la leuc√©mie humaine √† cellules T, d'un groupe de r√©trovirus de la leuc√©mie bovine, d'un groupe de r√©trovirus de type D, d'un groupe li√© √† la leuc√©mie du rat et d'un groupe de lentivirus.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Utilisation de la revendication 13, dans laquelle la prot√©ine contenant le doigt de zinc fait partie d'un virus intact.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Utilisation de la revendication 8, comprenant en outre √† d√©tecter la dissociation de l'ion m√©tallique du doigt de zinc de la prot√©ine contenant le doigt de zinc.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Utilisation de la revendication 15, dans laquelle la d√©tection de la dissociation de l'ion m√©tallique est r√©alis√©e en utilisant une m√©thode choisie parmi le groupe compos√© d'une √©lectrophor√®se capillaire, d'un immunotransfert, d'une r√©sonance magn√©tique nucl√©aire (RMN), d'une chromatographie liquide √† haute performance (HPLC), d'une d√©tection de la lib√©ration de zinc-65 radioactif, d'une d√©tection de fluorescence et d'une d√©tection de mobilit√© dans un gel.</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>Utilisation d'une composition pour inactiver un virus, l'utilisation comprenant mettre en contact un virus <i>in vitro</i> avec une composition selon la revendication 3, la composition comprenant un compos√© selon la revendication 1 ou des sels pharmaceutiquement acceptables de celui-ci, le fait de mettre le virus au contact de ladite composition inactivant le virus.</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>Utilisation de la revendication 17, dans laquelle le r√©trovirus est choisi parmi le groupe compos√© d'un HIV-1, un HIV-2, un SIV, un BIV, un EIAV, un Visna, un CaEV, un HTLV-1, un BLV, un MPMV, un MMTV, un RSV, un MuLV, un FeLV, un BaEV et un SSV.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>Utilisation de la revendication 18, dans laquelle le virus est un r√©trovirus HIV-1.<!-- EPO <DP n="60"> --></claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>Utilisation de la revendication 18, dans laquelle le virus est choisi parmi le groupe compos√© d'un r√©trovirus d√©riv√© d'un groupe de r√©trovirus de sarcome aviaire et de leucose, un groupe de r√©trovirus de type B de mammif√®re, un groupe de r√©trovirus de leuc√©mie humaine √† cellules T et de leuc√©mie bovine, un groupe de r√©trovirus de type D, un groupe li√© √† la leuc√©mie du rat et un groupe de lentivirus.</claim-text></claim><claim id="c-fr-01-0021" num="0021"><claim-text>Utilisation du compos√© selon l'une des revendications 1 ou 2 pour la fabrication d'un m√©dicament pour le traitement de maladies r√©trovirales.</claim-text></claim><claim id="c-fr-01-0022" num="0022"><claim-text>Utilisation de la composition selon l'une des revendications 3 √† 7 pour la fabrication d'un m√©dicament pour le traitement de maladies r√©trovirales.</claim-text></claim><claim id="c-fr-01-0023" num="0023"><claim-text>Utilisation du compos√© selon l'une des revendications 1 ou 2 pour la fabrication d'un microbicide topique pour emp√™cher la transmission de maladies r√©trovirales.</claim-text></claim><claim id="c-fr-01-0024" num="0024"><claim-text>Utilisation de la composition selon l'une des revendications 3 √† 7 pour la fabrication d'un microbicide topique pour emp√™cher la transmission d'une infection virale dans des maladies r√©trovirales.</claim-text></claim></claims><drawings mxw-id="PDW16672799" load-source="patent-office"><!-- EPO <DP n="61"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="165" he="228" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
